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With recent outbreaks of Elizabethkingia affecting the United States, it is important to further understand the method of action that this bacterium uses to infect patients. Given that Elizabethkingia is not regarded as a pathogen when found in nature, but has developed several advantages in antibiotic resistance, the sheer flexibility and variability of this organism to evade host immunity and pharmacological responses is cause for awe and alarm. Within this paper we will analyze the importance of Elizabethkingia as a pathogen, its proteophylogenetic importance as a carrier of β lactamases and the further development of a β lactamase library for the identification of these genes and proteins in future strains and other organisms.  
Generally we find no cause of alarm when we speak of the Elizabethkingia Genus, as we see that it is a naturally ubiquitous gram-negative rod bacterium pertaining to the commensal bacteria of certain fish and amphibians. Elizabeth King for who the bacteria was named after was the first individual to isolate Elizabethkingia and originally dubbed it Flavobacterium meningosepticum in 1959. The reasoning behind this naming was due to the morphological characteristics of this bacterium and its ability to cause the ailments of sepsis and meningitis in infantile patients1.  Yet with the dawn of the age of genetics and the ability to fully sequence the DNA of microorganisms, the world of phylogeny was 
turned upside down and given new life through the process of 16s rRNA sequencing and categorization. Once this analysis was done to the Genus Chryseobacterium (which was the new house of Elizabethkingia since 1994), it was seen that the organisms for C. meningosepticum and C. miricola branched off together and housed their own Genus as opposed to the rest of the Chryseobacterium2. 
 
Fig 1. Elizabethkingia blood agar spread plates26 
According to Bergey’s Manual of Systematics of Archaea and Bacteria, Elizabethkingia is characterized as 
 “Straight, single rods with rounded ends, typically 0.5 μm wide and variable in length, 
often forming filaments. Do not form endospores. Spherical degenerative forms do not appear 
in ageing liquid cultures. Nonmotile. Flagellar motility, gliding movement, and swarming 
growth have not been reported. Colonies are typically nonpigmented or weakly yellow 
pigmented, circular, convex, smooth and shiny, with entire edges, and up to 2 mm in diameter. 
A strong aromatic odor is produced. Gram-stain-negative. Obligately aerobic, having a strictly 
respiratory type of metabolism with oxygen as the terminal electron acceptor. Nitrate is not 
reduced. Chemoorganotrophic. Growth occurs at 22–37°C, but not at 5 or 42°C. Growth occurs 
readily on the usual commercial media. No growth factors are required. Growth on seawater 
media is possible. Growth on cetrimide and MacConkey agars is slow and weak, but is also 
strain-dependent. Catalase, oxidase, phosphatase, and β-galactosidase activities are present. 
Acid, but no gas, is produced from a number of carbohydrates in media with low peptone 
concentrations. Strong proteolytic activity occurs. Esculin, gelatin, and casein are hydrolyzed, 
but agar is not. Malonate is not utilized. Resistant to a wide range of antimicrobial agents. 
Menaquinone MK-6 is the predominant respiratory quinone. Predominant cellular fatty acids 
are C15:0 iso, C17:0 iso 3-OH, C17:1 iso ω9c, and summed feature 4 (comprising C15:0 iso 2-
OH and/or C16:1 ω7c/t). As they are ubiquitous in soil and freshwater, strains of 
Elizabethkingia meningoseptica occasionally occur in the hospital environment and clinical 
specimens; they are opportunistic pathogens of humans and various animals.”3  
Pathology & Virulence 
Elizabethkingia works as an opportunistic nosocomial pathogen mainly affecting premature births and infants. Given that these individuals are not fully immunocompetent, it has also been shown that immunodeficient individuals are at risk for infections of Elizabethkingia. With its optimal conditions of growth being right around room temperature and its ability to grow on freshwater show, medical equipment that is not properly sanitized or tap water can be prime sources of infection. Among the list of 
nosocomial infections that Elizabethkingia is known to cause we have: meningitis in immunocompromised adults, pneumonia, post-operative bacteremia endocarditis. More recently and surprisingly, Elizabethkingia has been found in a dire case of necrotizing fasciitis in a diabetic patient and infecting soft tissue thus leading to sepsis within fully immunocompetent patients 48 cases of Elizabethkingia infection resulting in 17 fatalities were reported in Wisconsin over a 5-month period beginning in November 20154,5,6. and once again in 2016 nine people were confirmed dead due to complications from an infection of Elizabethkingia. 
 
Fig 2. Demonstrates the effects of necrotizing fasciitis.4 
As are most nosocomial opportunistic pathogens, Elizabethkingia demonstrates a high level of antibiotic resistance, and therefore serves as a perfect candidate for proteomic and enzymatic study. Elizabethkingia not only contains the genes necessary for the production of aminoglycosides, tetracycline, and chloramphenicol but its most interesting method of evading destruction is its application of a broad variety of Β Lactamases. 
The Categorization of Β Lactamases 
There are two methods by which b-lactamases are classified. Molecular chracteristics or functional properties offer us accurate descriptions of what the structure and therefore function the b-Lactamases offer. For the purposes of this paper we have chosen to bioinformatically analyze the molecular designations from classes A, B, C, and D. These individual classes serve to delineate the b-lactamases according to their primary structure and the domains that can be predicted due to their broad range conservation. In cases were clinical relevance is saught after, the functional classification method can be applied. This method divides b-lactamases into 3 groups (1,2,3) based on the substrates they are specific for and the treatment that they may require. Furthermore we can acquiesce subgroups, within the molecular classification method through functionality and merge the two methods this can be seen by the use of terms such as extended-spectrum b-lactamases, or ESBLs, and inhibitor-resistant TEM, or IRT, b-lactamases.(Bush) 
Why B-Lactamases? 
B-lactam antibiotics are commonly utilized as broad spectrum antibiotics for the treatment of systemic and localized infections. Given the high reliance on these antibiotics 












Clustal Omega was utilized to create the phylogenetic tree Newicker sequences by using seeded guide trees and HMM profile-profile techniques to generate multiple sequence alignments between the known bla sequences and our candidate sequences. 
Multiple Sequence Alignment 
A Multiple sequence alignment was done with our candidate b-lactamase sequences and known β lactamases of classes A,B,C and D. A multiple sequence alignment (MSA) is a sequence alignment of three or more biological sequences in the case of our analysis, these sequences were single letter protein sequences. Clustal produced results that allowed us to confirm sequence homology between our candidates of the Class A as they met the guidelines put together by the NIH for serine catalyzed b-lactamases. Clustal was run with numbers and the descriptions offered tell us the following:*aa found in all sequences, : aa found in most sequences, .aa found in many sequences. Single amino acid or nucleotide changes appear as differing characters in a single alignment column, and insertion or deletion mutations appear as hyphens in one or more of the sequences in the alignment. 
Treeview ETE 
Newick format produced by Clustal Omega was utilized to view a Python based phylogenetic tree through ETEtoolkit 
NCBI Conserved Domain Database 
















Phylogenetic Tree of Classified B-Lactamases 
Multiple Sequence Alignment of Class A and C SBLs with motif localization  
 
CLUSTAL O(1.2.1) multiple sequence alignment 
 
 
AAM74565.1|blaCARB-7|PSE         -----------------MKSLLVFALLMPSVVFASSSKFQSVEQEIKGIESSLSARIGVA 43 
AAD19217.1|blaCARB-6|PSE         -----------------MKFLLAFSLLIPSVVFASSSKFQQVEQDVKAIEVSLSARIGVS 43 
BAA02497.1|blaCARB-12|PSE        -----------------MKFLLVFSLLIPSVVFASSSKFRQVEQDVKAIEVSLSARIGVS 43 
AAK96394.1|blaCARB-1|PSE         -----------------MKFLLAFSLLIPSVVFASSSKFQQVEQDVKAIEVSLSARIGVS 43 
AAA25740.1|blaCARB-2|PSE         MLLYKMCDNQNYGVTY-MKFLLAFSLLIPSVVFASSSKFQQVEQDVKAIEVSLSARIGVS 59 
AAG23870.1|blaCARB-11|PSE        -----------------MKFLLAFSLLIPSVVFASSSKFQQVEQDVKAIEVSLSARIGVS 43 
E.men_ATCC13253_bla759|SBL       -----------MT--FIKTYFTSLLFVLGIININAQTTNNELKKRIENIITGKKADVGVS 47 
E.ano_Ag1_bla3533|SBL            ------------M--AKKAILGIMALLMSLPFFSQVHENTVLKKTLESIISGKRATVGIS 46 
E.mir_ATCC33958_bla1019|SBL      ------------M--AKKAILGIIALLMSLSFFSQVHENTVLKKTLESIISGKKATVGIS 46 
AEI54993.1|blaPER-7|class        ---------MNVIIKAVVTASTLLM-VSFSSFET-SAQSPLLKEQIESIVIGKKATVGVA 49 
BAP39824.1|blaPER-8|class        ---------MNVIIKAVVTASTLLM-VSFSSFET-SAQSPLLKEQIESIVIEKKATVGVA 49 
BAU25894.1|blaPER-9|class        ---------MNVIIKAVVTASTLLM-VSFSSFET-SAQSPLLKEQIESIVIGKKATVGVA 49 
ACN22483.1|blaPER-5|class        ---------MNVIIKAVVTASTLLM-VSFSSFET-SAQSPLLKGQIESIVIGKKATVGVA 49 
ACE77058.1|blaPER-4|class        ---------MNVIIKAVVTASTLLM-VSFSSFET-SAQSPLLKEQIESIVIGKKATVGVA 49 
AAU89132.1|blaPER-3|class        ---------MNVIIKAVVTASTLLM-VSFSSFET-SAQSPLLKEQIESIVIGKKATVGVA 49 
CAA79968.1|blaPER-1|class        ---------MNVIIKAVVTASTLLM-VSFSSFET-SAQSPLLKEQIESIVIGKKATVGVA 49 
ADD80743.1|blaPER-6|class        ---------MNVIAKGVFTTTALLM-LSLSSWVV-SAQSPLLKEQIETIVTGKKATVGVA 49 
CAA63714.1|blaPER-2|class        ---------MNVITKCVFTASALLM-LGLSSFVV-SAQSPLLKEQIETIVTGKKATVGVA 49 
AMJ32272.1|blaVEB-17|class       ---------MKIV----KRILLVLL-SLFFTIAYSNAQTDNLTLKIENVLKAKNARIGVA 46 
AJH76942.1|blaVEB-10|class       ---------MKIV----KRILLVLL-SLFFTIVYSNAQTDNLTLKIENVLKAKNARIGVA 46 
ALB25886.1|blaVEB-15|class       ---------MKIV----KRILLVLL-SLFFTVVYSNAQTDNLTLKIENVLKAKNARIGVA 46 
AMJ32273.1|blaVEB-14|class       ---------MKIV----KRILLVLL-SLFFTVVYSNAQTDNLTLKIENVLKAKNARIGVA 46 
ALB25884.1|blaVEB-13|class       ---------MKIV----KRILLVLL-SLFFTVVYSNAQTDNLTLKIENVLKAKNARIGVA 46 
AKO63208.1|blaVEB-11|class       ---------MKIV----KRILLVLL-SLFFTIVYSNAQTDNLTLKIENVLKEKNARIGVA 46 
ACA34904.1|blaVEB-6|class        ---------MKIV----KRILLVLL-SLFFTVVYSNAQADNLTLKIENVLKAKNARIGVA 46 
ABM54868.1|blaVEB-4|class        ---------MKIV----KRILLVLL-SLFFTIVYSNAQADNLTLKIENVLKAKNARIGVA 46 
AAS48620.1|blaVEB-3|class        ---------MKIV----KRILLVLL-SLFFTVVYSNAQTDNLTLKIENVLKAKNARIGVA 46 
AAK29174.1|blaVEB-2|class        ---------MKIV----KRILLVLL-SLFFTIVYSNAQADNLTLKIENVLKAKNARIGVA 46 
AAD01435.1|blaVEB-1|class        ---------MKIV----KRILLVLL-SLFFTIVYSNAQTDNLTLKIENVLKAKNARIGVA 46 
AAK14293.1|blaVEB-9|class        ---------MKIV----KRILLVLL-SLFFTVVYSNAQTDNLTLKIENVLKAKNARIGVA 46 
ACO56763.1|blaVEB-7|class        ---------MKIV----KRILLVLL-SLFFTVEYSNAQTDNLTLKIENVLKAKNARIGVA 46 
ALB25887.1|blaVEB-16|class       ---------MKIV----KRILLVLL-SLFFTVEYSNAQTDNLTLKIENVLKAKNARIGVA 46 
AKO63209.1|blaVEB-12|class       ---------MKIV----KRILLVLL-SLFFTVEYSNAQTDNLTLKIENVLKAKNARIGVA 46 
ABN80430.1|blaVEB-5|class        ---------MKIV----KRILLVLL-SLFFTVEYSNAQTDNLTLKIENVLKAKNARIGVA 46 
AGH33739.1|blaVEB-8|class        ---------MKIV----KRILLVLL-SLFFTVEYSNAQTDNLTLKIENVLKAKNARIGVA 46 
E.men_ATCC13253_bla785|SBL       ------------M----KKFTFLF--LLICQFSFAQQ--VSLLKEINNITKGKKATVAVS 40 
E.ano_Ag1_bla3289|SBL            ------------M----KRISIIF--LFFSLFVFSQHSKPELLEKINTITKGKKATVAVS 42 
E.mir_ATCC33958_bla2641|SBL      ------------M----KKIILLF--LLTGQFVLAQH--TSILNDINAVTKDKKATVAVS 40 
                                                        :                 :   :: :     * :.:: 
 
AAM74565.1|blaCARB-7|PSE         ILDTQNG-ESWDYNGDQRFPLTSTFKTIACAKLLYDAEHGKVNLNSTVEIKKADLV--TY 100 
AAD19217.1|blaCARB-6|PSE         VLDTQNG-EYWDYNGNQRFPLTSTFKTIACAKLLYDAEQGKVNPNSTVEIKKADLV--TY 100 
BAA02497.1|blaCARB-12|PSE        VLDTQNG-EYWDYNGNQRFPLTSTFKTIACAKLLYDAEQGKVNPNSTVEIKKADLV--TY 100 
AAK96394.1|blaCARB-1|PSE         VLDTQNG-EYWDYNGNQRFPLTSTFKTIACAKLLYDAEQGKVNPNSTVEIKKADLV--TY 100 
AAA25740.1|blaCARB-2|PSE         VLDTQNG-EYWDYNGNQRFPLTSTFKTIACAKLLYDAEQGKVNPNSTVEIKKADLV--TY 116 
AAG23870.1|blaCARB-11|PSE        VLDTQNG-EYWDYNGNQRFPLTSTFKTIACAKLLYDAEQGKVNSNSTVEIKKADLV--TY 100 
E.men_ATCC13253_bla759|SBL       IIGGNKN-DKVQINGNQLYPMLSTFKFPIALTVLHKVEKGELKMSQKIFIKKEELLDNTW 106 
E.ano_Ag1_bla3533|SBL            IMGPDTK-EVTRINGDQMLPMLSTVKFPLALTVLHEVEKGKLSMDQKLFIKKEELLEDTW 105 
E.mir_ATCC33958_bla1019|SBL      VIGPDTK-EVTGINGDQMLPMLSTVKFPLALTVLHEVEKGKLSMAQKLFIKKEELLEDTW 105 
AEI54993.1|blaPER-7|class        VWGPDDL-EPLLINPFEKFPMQSVFKLHLAMLVLHQVDQGKLDLNQTVIVNRAKVLQNTW 108 
BAP39824.1|blaPER-8|class        VWGPDDL-EPLLINPFEKFPMQSVFKLHLAMLVLHQVDQGKLDLNQTVIVNRAKVLQNTW 108 
BAU25894.1|blaPER-9|class        VWGPDDL-EPLLINPFEKFPMQSVFKLHLAMLVLHQVDQGKLDLNQTVIVNRAKVLQNTW 108 
ACN22483.1|blaPER-5|class        VWGPDDL-EPLLINPFEKFPMQSVFKLHLAMLVLHQVDQGKLDLNQTVIVNRAKVLQNTW 108 
ACE77058.1|blaPER-4|class        VWGPDDL-EPLLINPFEKFPMQSVFKLHLAMLVLHQVDQGKLDLNQTVIVNRAKVLQNTW 108 
AAU89132.1|blaPER-3|class        VWGPDDL-EPLLINPFEKFPMQSVFKLHLAMLVLHQVDQGKLDLNQTVIVNRAKVLQNTW 108 
CAA79968.1|blaPER-1|class        VWGPDDL-EPLLINPFEKFPMQSVFKLHLAMLVLHQVDQGKLDLNQTVIVNRAKVLQNTW 108 
ADD80743.1|blaPER-6|class        VWGPDDL-EPLLVNPFEKFPMQSVFKMHLAMLVLHQVDQGKLDLNKTVAVNRAAVLQNTW 108 
CAA63714.1|blaPER-2|class        VWGPDDL-EPLLLNPFEKFPMQSVFKLHLAMLVLHQVDQGKLDLNQSVTVNRAAVLQNTW 108 
AMJ32272.1|blaVEB-17|class       IFNSNEK-DTLKINNDFHYPMQSVMKFPIALAVLSEIDKGNLSFEQKIEITPQDLLPKMW 105 
AJH76942.1|blaVEB-10|class       IFNSNEK-DTLKINNDFHFPMQSVMKFPIALAVLSEIDKGNLSFEQKIEITPQDLLPKMW 105 
ALB25886.1|blaVEB-15|class       IFNSNEK-DTLKINNDFHFPMQSVMKFPIALAVLSEIDKGNLSFEQKIEITPQDLLPKMW 105 
AMJ32273.1|blaVEB-14|class       IFNSNEK-DTLKINNDFHFPMQSVMKFPIALAVLSEIDKGNLSFEQKIEITPQDLLPKTW 105 
ALB25884.1|blaVEB-13|class       IFNSNEK-DTLKINNDFHFPMQSVMKFPIALAVLSEIDKGNLSFEQKIEITPQDLLPKTW 105 
AKO63208.1|blaVEB-11|class       IFNSNEK-DTLKINNDFHFPMQSVMKFPIALAVLSEIDKGNLSFEQKIEITPQDLLPKTW 105 
ACA34904.1|blaVEB-6|class        IFNSNEK-DTLKINNDFHFPMQSVMKFPIALAVLSEIDKGNLSFEQKIEITPQDLLPKMW 105 
ABM54868.1|blaVEB-4|class        IFNSNEK-DTLKINNDFHFPMQSVMKFPIALAVLSEIDKGNLSFEQKIEITPQDLLPKMW 105 
AAS48620.1|blaVEB-3|class        IFNSNEK-DTFKINNDFHFPMQSVMKFPIALAVLSEIDKGNLSFEQKIEITPQDLLPKTW 105 
AAK29174.1|blaVEB-2|class        IFNSNEK-DTLKINNDFHFPMQSVMKFPIALAVLSEIDKGNLSFEQKIEITPQDLLPKTW 105 
AAD01435.1|blaVEB-1|class        IFNSNEK-DTLKINNDFHFPMQSVMKFPIALAVLSEIDKGNLSFEQKIEITPQDLLPKTW 105 
AAK14293.1|blaVEB-9|class        IFNSNEK-DTLKINNDFHFPMQSVMKFPIALAVLSEIDKGNLSFEQKIEITPQDLLPKTW 105 
ACO56763.1|blaVEB-7|class        IFNSNEK-DTLKINNDFHFPMQSVMKFPIALAVLSEIDKGNLSFEQKIEITPQDLLPKTW 105 
ALB25887.1|blaVEB-16|class       IFNSNEK-DTLKINNDFHFPMQSVMKFPIALAVLSEIDKGNLSFEQKIEITPQDLLPKTW 105 
AKO63209.1|blaVEB-12|class       IFNSNEK-DTLKINNDFHFPMQSVMKFPIALAVLSEIDKGNLSFEQKIEITPQDLLPKTW 105 
ABN80430.1|blaVEB-5|class        IFNSNEK-DTLKINNDFHFPMQSVMKFPIALAVLSEIDKGNLSFEQKIEITPQDLLPKMW 105 
AGH33739.1|blaVEB-8|class        IFNSNEK-DTLKINNDFHFPMQSVMKFPIALAVLSEIDKGNLSFEQKIEITPQDLLPKMW 105 
E.men_ATCC13253_bla785|SBL       VSGIEDNFQLSNNNGQLKMPMMSVFKFHIALAVLNQADKGNLTLDQKILVKKSDLHENTW 100 
E.ano_Ag1_bla3289|SBL            VLGIENDFQFSNANGNLKMPMLSVFKFHIALAVLNQVDKGNLTLDQKILIKKSDLLENTW 102 
E.mir_ATCC33958_bla2641|SBL      VLGIENEFQFSNTNGNLKMPMLSVFKFHIALAVLNQVDKGNLTLDQKILIKKSDLLENTW 100 






AAM74565.1|blaCARB-7|PSE         SPVLEKQVGKP--ITLSDACLATMTTSDNTAANIVINAVGDPKSITDFLRQIGDKETRLD 158 
AAD19217.1|blaCARB-6|PSE         SPVIEKQVGQA--ITLDDACFATMTTSDNTAANIILSAVGGPKGVTDFLRQIGDKETRLD 158 
BAA02497.1|blaCARB-12|PSE        SPVIEKQVGQA--ITLDDACFATMTTSDNTAANIILSAVGGSKGVTDFLRQIGDKETRLD 158 
AAK96394.1|blaCARB-1|PSE         SPVIEKQVGQA--ITLDDACFATMTTSDNTAANIILSAVGGPKGVTDFLRQIGDKETRLD 158 
AAA25740.1|blaCARB-2|PSE         SPVIEKQVGQA--ITLDDACFATMTTSDNTAANIILSAVGGPKGVTDFLRQIGDKETRLD 174 
AAG23870.1|blaCARB-11|PSE        SPVIEKQVGQA--ITLDDACFATMTTSDNTAANIILSAVGGPKGVTDFLRQIGDKETRLD 158 
E.men_ATCC13253_bla759|SBL       SPFLEKYPQGNISITLEDALMWMMCYSDNNLTDILIRLIGGTDTVQKFIGT---KDFIIK 163 
E.ano_Ag1_bla3533|SBL            SPFKEKYPQGNITITLEEALKWTVSYSDNNLTDILLRLIGGPETVQGFIDS---SSFIIK 162 
E.mir_ATCC33958_bla1019|SBL      SPFKEKYPQGNITITLEEALKWTVSYSDNNLTDILLRLIGGPETVQEFIDS---SSFIIK 162 
AEI54993.1|blaPER-7|class        APIMKAYQGDQFSVPVQQLLQYSVSHSDNVACDLLFELVGGPAALHDYIQSMGIKETAVV 168 
BAP39824.1|blaPER-8|class        APIMKAYQGDQFSVPVQQLLQYSVSHSDNVACDLLFELVGGPAALHDYIQSMGIKETAVV 168 
BAU25894.1|blaPER-9|class        APIMKAYQGDEFSVPVQQLLLYSVSHSDNVACDLLFELVGGPAALHDYIQSMGIKETAVV 168 
ACN22483.1|blaPER-5|class        APIMKAYQGDEFSVPVQQLLQYSVSHSDNVACDLLFELVGGPAALHDYIQSMGIKETAVV 168 
ACE77058.1|blaPER-4|class        APIMKAYQGDEFSVPVQQLLQYSVSHTDNVACDLLFELVGGPAALHDYIQSMGIKETAVV 168 
AAU89132.1|blaPER-3|class        APIMKAYQGDEFSVPVQQLLQYSVSLSDNVACDLLFELVGGPAALHDYIQSMGIKETAVV 168 
CAA79968.1|blaPER-1|class        APIMKAYQGDEFSVPVQQLLQYSVSHSDNVACDLLFELVGGPAALHDYIQSMGIKETAVV 168 
ADD80743.1|blaPER-6|class        SPMMKDHQGDEFTVTVQQLLQYSVSHSDNVACDLLFELVGGPAALHAYIQSLGIKETEVV 168 
CAA63714.1|blaPER-2|class        SPMMKDHQGDEFTVAVQQLLQYSVSHSDNVACDLLFELVGGPQALHAYIQSLGVKEAAVV 168 
AMJ32272.1|blaVEB-17|class       SPIKEEFPNGT-TLTIEQILNYTVSESDNIGCDILLKLIGGTDSVQKFLNANHFTDISIK 164 
AJH76942.1|blaVEB-10|class       SPIKEEFPNGT-TLTIEQILNYTVSESDNIGCDILLKLIGGTDSVQKFLNANHFTDISIK 164 
ALB25886.1|blaVEB-15|class       SPIKEEFPNGT-TLTIEQILNYTVSESDNIGCDILLKLIGGTDSVQKFLNANHFTDISIK 164 
AMJ32273.1|blaVEB-14|class       SPIKEEFPNGT-TLTIEQILNYTVSESDNIGCDILLKLIGGTDSVQKFLNANHFTDISIK 164 
ALB25884.1|blaVEB-13|class       SPIKEEFPNGT-TLTIEQILNYTVSESDNIGCDILLKLIGGTDSVQKFLNANHFTDISIK 164 
AKO63208.1|blaVEB-11|class       SPIKEEFPNGT-TLTIEQILNYTVSESDNIGCDILLKLIGGTDSVQKFLNANHFTDISIK 164 
ACA34904.1|blaVEB-6|class        SPIKEEFPNGT-TLTIEQILNYTVSESDNIGCDILLKLIGGTDSVQKFLNANHFTDISIK 164 
ABM54868.1|blaVEB-4|class        SPIKEEFPNGT-TLTIEQILNYTVSESDNIGCDILLKLIGGTDSVQKFLNANHFTDISIK 164 
AAS48620.1|blaVEB-3|class        SPIKEEFPNGT-TLTIEQILNYTVSESDNIGCDILLKLIGGTDSVQKFLNANHFTDISIK 164 
AAK29174.1|blaVEB-2|class        SPIKEEFPNGT-TLTIEQILNYTVSESDNIGCDILLKLIGGTDSVQKFLNANHFTDISIK 164 
AAD01435.1|blaVEB-1|class        SPIKEEFPNGT-TLTIEQILNYTVSESDNIGCDILLKLIGGTDSVQKFLNANHFTDISIK 164 
AAK14293.1|blaVEB-9|class        SPIKEEFPNGT-TLTIEQILNYTVSESDNIGCDILLKLIGGTDSVQKFLNANHFTDISIK 164 
ACO56763.1|blaVEB-7|class        SPIKEEFPNGT-TLTIEQILNYTVSESDNIGCDILLKLIGGTDSVQKFLNANHFTDISIK 164 
ALB25887.1|blaVEB-16|class       SPIKEEFPNGT-TLTIEQILNYTVSESDNIGCDILLKLIGGTDSVQKFLNANHFTDISIK 164 
AKO63209.1|blaVEB-12|class       SPIKEEFPNGT-TLTIEQILNYTVSESDNIGCDILLKLIGGTDSVQKFLNANHFTDISIK 164 
ABN80430.1|blaVEB-5|class        SPIKEEFPNGT-TLTIEQILNYTVSESDNIGCDILLKLIGGTDSVQKFLNANHFTDISIK 164 
AGH33739.1|blaVEB-8|class        SPIKEEFPNGT-TLTIEQILNYTVSESDNIGCDILLKLIGGTDSVQKFLNANHFTDISIK 164 
E.men_ATCC13253_bla785|SBL       SPIREKYPQGNVNLPLSEIIYYTVAQSDNNGCDILLRLLGGTQAVQKFVNSKGIKNIQIK 160 
E.ano_Ag1_bla3289|SBL            SPLREKYPDGNVELPLSEIITYTVAQSDNNGCDILLRLIGGTKTVQKLMDVNGIKNFQIK 162 
E.mir_ATCC33958_bla2641|SBL      SPLREKYPNGNVEVPLSEIITYTVAQSDNNGCDILLRLIGGTKTVQKLMDVNGVKNFQIK 160 







AAM74565.1|blaCARB-7|PSE         RVEPELNEG-KLGDLRDTTTPNAITSTLNQLL--FGSTLSEASQKKLESWMVNNQVTGNL 215 
AAD19217.1|blaCARB-6|PSE         RIEPDLNEG-KLGDLRDTTTPKAIASTLNQLL--FGSTLSEASQKKLESWMVNNQVTGNL 215 
BAA02497.1|blaCARB-12|PSE        RIEPDLNEG-KLGDLRDTTTPKAIASTLNKFL--FGSALSEMNKKKLESWMVNNQVTGNL 215 
AAK96394.1|blaCARB-1|PSE         RIEPDLNEG-KLGDLRDTTTPKAIASTLNKFL--FGSALSEMNQKKLESWMVNNQVTGNL 215 
AAA25740.1|blaCARB-2|PSE         RIEPDLNEG-KLGDLRDTTTPKAIASTLNKFL--FGSALSEMNQKKLESWMVNNQVTGNL 231 
AAG23870.1|blaCARB-11|PSE        RIEPDLNEG-KLGDLRDTTTPKAIASTLNKFL--FGSALSEMNQKKLESWMVNNQVTGNL 215 
E.men_ATCC13253_bla759|SBL       NDEEDMHKA-WDSQFINKITPNRATQLLDKFY--QGKILNRVNTKWLYEAMLNNKTGLKR 220 
E.ano_Ag1_bla3533|SBL            NDEEGMHKD-WDSQFINKITPNSAALLLQEFS--NGKILNKAHTQWLYNAMLNNASGKKR 219 
E.mir_ATCC33958_bla1019|SBL      NDEEGMHKD-WDSQFINKITPNYATLLLQEFS--NGKILNKAHTQWLYNAMLNNASGKKR 219 
AEI54993.1|blaPER-7|class        ANEAQMHAD-DQVQYQNWTSMKGAAEILKKFE--QKTQLSETSQALLWKWMVETTTGPER 225 
BAP39824.1|blaPER-8|class        ANEAQMHAD-DQVQYQNWTSMKGAAEILKKFE--QKTQLSETSQALLWKWMVETTTGPER 225 
BAU25894.1|blaPER-9|class        ANEAQMHAD-DQVQYQNWTSMKGAAEILKKFE--QKTQLSETSQALLWKWMVETTTGPER 225 
ACN22483.1|blaPER-5|class        ANEAQMHAD-DQVQYQNWTSMKGAAEILKKFE--QKTQLSETSQALLWKWMVETTTGPER 225 
ACE77058.1|blaPER-4|class        ANEAQMHAD-DQVQYQNWTSMKGAAEILKKFE--QKTQLSETSQALLWKWMVETTTGPER 225 
AAU89132.1|blaPER-3|class        ANEAQMHAD-DQVQYQNWTSMKGAAEILKKFE--QKTQLSETSQALLWKWMVETTTGPER 225 
CAA79968.1|blaPER-1|class        ANEAQMHAD-DQVQYQNWTSMKGAAEILKKFE--QKTQLSETSQALLWKWMVETTTGPER 225 
ADD80743.1|blaPER-6|class        ANEAQMHAD-DQVQYKNWTSMKAAAQLLRKFE--QKKQLSETSQALLWKWMVETTTGPQR 225 
CAA63714.1|blaPER-2|class        ANEAQMHAD-DQVQYQNWTSMKAAAQVLQKFE--QKKQLSETSQALLWKWMVETTTGPQR 225 
AMJ32272.1|blaVEB-17|class       ANEEQMHKD-WNTQYQNWATPTAMNKLLIDTYNNKNQLLSKKSYDFIWKIMRETTTGSNR 223 
AJH76942.1|blaVEB-10|class       ANEEQMHKD-WNTQYQNWATPTAMNKLLIDTYNNKNQLLSKKSYDFIWKIMRETTTGSNR 223 
ALB25886.1|blaVEB-15|class       ANEEQMHKD-WNTQYQNWATPTAMNKLLIDTYNNKNQLLSKKSYDFIWKIMRETTTGSNR 223 
AMJ32273.1|blaVEB-14|class       ANEEQMHKD-WNTQYQNWATPTAMNKLLIDTYNNKNQLLSKKSYDFIWKIMRET-TGSNR 222 
ALB25884.1|blaVEB-13|class       ANEEQMHKD-WNTQYQNWATPTAMNKLLIDTYNNKNQLLSKKSYDFIWKIMRETTAGSNR 223 
AKO63208.1|blaVEB-11|class       ANEEQMHKD-WNTQYQNWATPTAMNKLLIDTYNNKNQLLSKKSYDFIWKIMRETTTGSNR 223 
ACA34904.1|blaVEB-6|class        ANEEQMHKD-WNTQYQNWATPTAMNKLLIDTYNNKNQLLSKKSYDFIWKIMRETTTGSNR 223 
ABM54868.1|blaVEB-4|class        ANEEQMHKD-WNTQYQNWATPTAMNKLLIDTYNNKNQLLSKKSYDFIWKIMRETTTGSNR 223 
AAS48620.1|blaVEB-3|class        ANEEQMHKD-WNTQYQNWATPTAMNKLLIDTYNNKNQLLSKKSYDFIWKIMRETTTGSNR 223 
AAK29174.1|blaVEB-2|class        ANEEQMHKD-WNTQYQNWATPTAMNKLLIDTYNNKNQLLSKKSYDFIWKIMRETTTGSNR 223 
AAD01435.1|blaVEB-1|class        ANEEQMHKD-WNTQYQNWATPTAMNKLLIDTYNNKNQLLSKKSYDFIWKIMRETTTGSNR 223 
AAK14293.1|blaVEB-9|class        ANEEQMHKD-WNTQYQNWATPTAMNKLLIDTYNNKNQLLSKKSYDFIWKIMRETTTGSNR 223 
ACO56763.1|blaVEB-7|class        ANEEQMHKD-WNTQYQNWATPTAMNKLLIDTYNNKNQLLSKKSYDFIWKIMRETTTGSNR 223 
ALB25887.1|blaVEB-16|class       ANEEQMHKD-WNTQYQNWATPTAMNKLLIDTYNNKNQLLSKKSYDFIWKIMRETTTGSNR 223 
AKO63209.1|blaVEB-12|class       ANEEQMHKD-WNTQYQNWATPTAMNKLLIDTYNNKNQLLSKKSYDFIWKIMRETTAGSNR 223 
ABN80430.1|blaVEB-5|class        ANEEQMHKD-WNTQYQNWATPTAMNKLLIDTYNNKNQLLSKKSYDFIWKIMRETTTGSNR 223 
AGH33739.1|blaVEB-8|class        ANEEQMHKD-WNTQYQNWATPTAMNKLLIDTYNNKNQLLSKKSYDFIWKIMRETTAGSNR 223 
E.men_ATCC13253_bla785|SBL       HNEEEMHTKGVQVLYENYTTTSSMVKTLKSFY--KNMMISKKSTDFLMDIMLKTDTGMAK 218 
E.ano_Ag1_bla3289|SBL            YNEEEMHKNDVKTLYANYTTTASMVKTLKAFY--KGMFLSKRSTIFLMDIMTKTNTGMSK 220 
E.mir_ATCC33958_bla2641|SBL      YNEEEMHKNDVKALYANYTTTASMVKTLKAFY--KGMFLSKRSTIFLMDIMTRTNTGMAK 218 








AAM74565.1|blaCARB-7|PSE         LRSVLPVKWSIADRSGAGGF------GARSITAIVWSEEKKPIIVSIYLAQTEASMAERN 269 
AAD19217.1|blaCARB-6|PSE         LRSVLPVKWSIADRSGAGGF------GARSITAIVWSEEKKTIIVSIYLAQTEASMAERN 269 
BAA02497.1|blaCARB-12|PSE        LRSVLPAGWNIADRSGAGGF------GARSITAVVWSEHQAPIIVSIYLAQTQASMAERN 269 
AAK96394.1|blaCARB-1|PSE         LRSVLPAGWNIADRSGAGGF------GARSITAVVWSEHQAPIIVSIYLAQTQASMEERN 269 
AAA25740.1|blaCARB-2|PSE         LRSVLPAGWNIADRSGAGGF------GARSITAVVWSEHQAPIIVSIYLAQTQASMAERN 285 
AAG23870.1|blaCARB-11|PSE        LRSVLPAGWNIADRSGAGGF------GARSITAVVWSEHQAPIIVSIYLAQTQASMAERN 269 
E.men_ATCC13253_bla759|SBL       LKGKLAADIKVAHRSGTSFTNDAGMTGAINSYGIIELPKNKKTCNYGFCSRYL------- 273 
E.ano_Ag1_bla3533|SBL            LKGNLPAGVKIAHRTGTSFTNKEGMTGAINDYGIIELPGKKKIYIAVFVHNTYESFDESE 279 
E.mir_ATCC33958_bla1019|SBL      LKGNLPAGVKIAHRTGTSFTNKEGMTGAINDYGIIELPGKKKIYIAVFVHDTYESFEASE 279 
AEI54993.1|blaPER-7|class        LKGLLPAGTVVAHKTGTSG-VRAGKTAATNDLGIILLPDGRPLLVAVFVKDSAESSRTNE 284 
BAP39824.1|blaPER-8|class        LKGLLPAGTVVAHKTGTSG-VRAGKTAATNDLGIILLPDGRPLLVAVFVKDSAESSRTNE 284 
BAU25894.1|blaPER-9|class        LKGLLPAGTVVAHKTGTSG-IKAGKTAATNDLGIILLPDGRPLLVAVFVKDSAESSRTNE 284 
ACN22483.1|blaPER-5|class        LKGLLPAGTVVAHKTGTSG-IKAGKTAATNDLGIILLPDGRPLLVAVFVKDSAESSRTNE 284 
ACE77058.1|blaPER-4|class        LKGLLPAGTVVAHKTGTSG-IKAGKTAATNDLGIILLPDGRPLLVAVFVKDSAESSRTNE 284 
AAU89132.1|blaPER-3|class        LKGLLPAGTVVAHKTGTSG-IKAGKTAATNDLGIILLPDGRPLLVAVFVKDSAESSRTNE 284 
CAA79968.1|blaPER-1|class        LKGLLPAGTVVAHKTGTSG-IKAGKTAATNDLGIILLPDGRPLLVAVFVKDSAESSRTNE 284 
ADD80743.1|blaPER-6|class        LKGLLPAGTVVAHKTGTSG-VRAGKTAATNDIGVIMLPDGRPLLVAVFVKDSAESARTNE 284 
CAA63714.1|blaPER-2|class        LKGLLPAGTIVAHKTGTSG-VRAGKTAATNDAGVIMLPDGRPLLVAVFVKDSAESERTNE 284 
AMJ32272.1|blaVEB-17|class       LKGQLPKNTIVAHKTGTSG-INNGIAAATNDVGVITLPNGQLIFISVFVAESKETSEINE 282 
AJH76942.1|blaVEB-10|class       LKGQLPKNTIVAHKTGTSG-INNGIAAATNDVGVITLPNGQLIFISVFVAESKETSEINE 282 
ALB25886.1|blaVEB-15|class       LKGQLPKNTIVAHKTGTSG-INNGIAAATNDVGVITLPNGQLIFISVFVAESKETSEINE 282 
AMJ32273.1|blaVEB-14|class       LKGQLPKNTIVAHKTGTSG-INNGIAAATNDVGVITLPNGQLIFISVFVAESKETSEINE 281 
ALB25884.1|blaVEB-13|class       LKGQLPKNTIVAHKTGTSG-INNGIAAATNDVGVITLPNGQLIFISVFVAESKETSEINE 282 
AKO63208.1|blaVEB-11|class       LKGQLPKNTIVAHKTGTSG-INNGIAAATNDVGVITLPNGQLIFISVFVAESKETSEINE 282 
ACA34904.1|blaVEB-6|class        LKGQLPKNTIVAHKTGTSG-INNGIAAATNDVGVITLPNGQLIFISVFVAESKETSEINE 282 
ABM54868.1|blaVEB-4|class        LKGQLPKNTIVAHKTGTSG-INNGIAAATNDVGVITLPNGQLIFISVFVAESKETSEINE 282 
AAS48620.1|blaVEB-3|class        LKGQLPKNTIVAHKTGTSG-INNGIAAATNDVGVITLPNGQLIFISVFVAESKETSEINE 282 
AAK29174.1|blaVEB-2|class        LKGQLPKNTIVAHKTGTSG-INNGIAAATNDVGVITLPNGQLIFISVFVAESKETSEINE 282 
AAD01435.1|blaVEB-1|class        LKGQLPKNTIVAHKTGTSG-INNGIAAATNDVGVITLPNGQLIFISVFVAESKETSEINE 282 
AAK14293.1|blaVEB-9|class        LKGQLPKNTIVAHKTGTSG-INNGIAAATNDVGVITLPNGQLIFISVFVAESKETSEINE 282 
ACO56763.1|blaVEB-7|class        LKGQLPKNTIVAHKTGTSG-INNGITAATNDVGVITLPNGQLIFISVFVAESKETSEINE 282 
ALB25887.1|blaVEB-16|class       LKGQLPKNTIVAHKTGTSG-INNGIAAATNDVGVITLPNGQLIFISVFVAESKETSEINE 282 
AKO63209.1|blaVEB-12|class       LKGQLPKNTIVAHKTGTSG-INNGIAAATNDVGVITLPNGQLIFISVFVAESKETSEINE 282 
ABN80430.1|blaVEB-5|class        LKGQLPKNTIVAHKTGTSG-INNGIAAATNDVGVITLPNGQLIFISVFVAESKETSEINE 282 
AGH33739.1|blaVEB-8|class        LKGQLPKNTIVAHKTGTSG-INNGIAAATNDVGVITLPNGQLIFISVFVAESKETSEINE 282 
E.men_ATCC13253_bla785|SBL       LPGLLPNVKMARKTGSSGK-LPSGLTVAENDSGIVTLDNGKHFAIAVFVKNSTESEEINY 277 
E.ano_Ag1_bla3289|SBL            LPGLLPKVRMARKTGSSGK-MKNGLTIAENDSGIVTLANGKHYAIAVFVKDSMESEEVNC 279 
E.mir_ATCC33958_bla2641|SBL      LPGLLPKVKMARKTGSSGK-MKNGLTIAENDSGIITLANGKHYAIAVFVKDSMESEEVNC 277 
                                 * . *       .  .:.         * .  .::            :             
 
AAM74565.1|blaCARB-7|PSE         DAIVKIGRSIFEVYTSQSR----- 288 
AAD19217.1|blaCARB-6|PSE         DAIVKIGRSIFEVYTSQSR----- 288 
BAA02497.1|blaCARB-12|PSE        DAIVKIGRSIFDVYTSQSR----- 288 
AAK96394.1|blaCARB-1|PSE         DAIVKIGHSIFDVYTSQSR----- 288 
AAA25740.1|blaCARB-2|PSE         DAIVKIGHSIFDVYTSQSR----- 304 
AAG23870.1|blaCARB-11|PSE        DAIVKIGHSIFDVYTSQSR----- 288 
E.men_ATCC13253_bla759|SBL       ------------------------ 273 
E.ano_Ag1_bla3533|SBL            KIISDIGRAAYDYYTKK------- 296 
E.mir_ATCC33958_bla1019|SBL      KIISDIGRATYDYYTKK------- 296 
AEI54993.1|blaPER-7|class        AIIAQVAQAAYQFELKKLSALSPN 308 
BAP39824.1|blaPER-8|class        AIIAQVAQAAYQFELKKLSALSPN 308 
BAU25894.1|blaPER-9|class        AIIAQVAQTAYQFELKKLSALSPN 308 
ACN22483.1|blaPER-5|class        AIIAQVAQTAYQFELKKLSALSPN 308 
ACE77058.1|blaPER-4|class        AIIAQVAQTAYQFELKKLSALSPN 308 
AAU89132.1|blaPER-3|class        AIIAQVAQTAYQFELKKLSALSPN 308 
CAA79968.1|blaPER-1|class        AIIAQVAQTAYQFELKKLSALSPN 308 
ADD80743.1|blaPER-6|class        AIIAQVAQAAYQFELKKLSAVSPD 308 
CAA63714.1|blaPER-2|class        AIIAQVAQAAYQFELKKLSAVSPD 308 
AMJ32272.1|blaVEB-17|class       KIISDIAKITWDYYLNK------- 299 
AJH76942.1|blaVEB-10|class       KIISDIAKITWDYYLNK------- 299 
ALB25886.1|blaVEB-15|class       KIISDIAKITWDYYLNK------- 299 
AMJ32273.1|blaVEB-14|class       KIISDIAKITWNYYLNK------- 298 
ALB25884.1|blaVEB-13|class       KIISDIAKITWNYYLNK------- 299 
AKO63208.1|blaVEB-11|class       KIISDIAKITWNYYLNK------- 299 
ACA34904.1|blaVEB-6|class        KIISDIAKITWNYYLNK------- 299 
ABM54868.1|blaVEB-4|class        KIISDIAKITWNYYLNK------- 299 
AAS48620.1|blaVEB-3|class        KIISDIAKITWNYYLNK------- 299 
AAK29174.1|blaVEB-2|class        KIISDIAKITWNYYLNK------- 299 
AAD01435.1|blaVEB-1|class        KIISDIAKITWNYYLNK------- 299 
AAK14293.1|blaVEB-9|class        KIISDIAKITWNYYLNK------- 299 
ACO56763.1|blaVEB-7|class        KIISDIAKITWNYYLNK------- 299 
ALB25887.1|blaVEB-16|class       KIISDIAKITWNYYLNK------- 299 
AKO63209.1|blaVEB-12|class       KIISDIAKITWNYYLNK------- 299 
ABN80430.1|blaVEB-5|class        KIISDIAKITWNYYLNK------- 299 
AGH33739.1|blaVEB-8|class        KIISDIAKITWNYYLNK------- 299 
E.men_ATCC13253_bla785|SBL       SIIAQVSKAVFDYLNNTK------ 295 
E.ano_Ag1_bla3289|SBL            GMIAQVSKIVWDALNKKNKP---- 299 
E.mir_ATCC33958_bla2641|SBL      GMIAQISKIVWDTLNKKNKP---- 297 
 
C Group 3 




CAK95242.1|blaADC-19|class                          MRFKKISCLLLS----PLFIFNTSIYAGNTSKEQEI---------KKLVDQNFKPLLEKY 47 
ACN62075.1|blaADC-18|class                          MRFKKISCLLLP----PLFIFSTSIYAGNTPKEQEV---------KKLVDQNFKPLLDKY 47 
CAK95238.1|blaADC-23|class                          MRFKKISCLLLP----PLFIFSTSIYAGNTPKEQEV---------KKLVDQNFKPLLDKY 47 
AIT76084.1|blaACC-4|cephalosporin-hydrolyzing       -MRKKMQNTLKLLSVITCLAATVQGALAANIDESKI---------KDTVDDLIQPLMQKN 50 
AAF86700.1|blaACC-1d|cephalosporin-hydrolyzing      -MRKKMQNTLKLLSVITCLAATAQGALAANIDESKI---------KDTVDDLIQPLMQKN 50 
AAF86694.1|blaACC-1b|cephalosporin-hydrolyzing      -MRKKMQNTLKLLSVITCLAATAQGALAANIDESKI---------KDTVDDLIQPLMQKN 50 
AAF86699.1|blaACC-1a|cephalosporin-hydrolyzing      -MRKKMQNTLKLLSVITCLAATAQGALAANIDESKI---------KDTVDDLIQPLMQKN 50 
BAP68758.1|blaACT-35|cephalosporin-hydrolyzing      MMKKSLCC--------ALLLGISCSALATPVSEKQL---------AEVVANTVTPLMKAQ 43 
AFU25650.1|blaACT-12|cephalosporin-hydrolyzing      MMKKSLCC--------ALLLSTSCAALAAPLSETQL---------AKVVERTVTPLMKAQ 43 
AHM76774.1|blaACT-22|cephalosporin-hydrolyzing      MMKKSLCC--------ALLLSTSCAALAAPMSETQL---------AKVVARTVTPLMKAQ 43 
E.mir_ATCC33958_bla719                              --------------------------------------------------------MKYS 4 
E.mir_ATCC33958_bla4255|SBL                         ---MKTSSKFL-----AALLFISSFSFGQNISKK--IDSII------------SDNYKKN 38 
E.men_13253_bla2764                                 -MIKKLAFLFL-----FALLFSCKTEQQKTIDRNVIVDSTITAFQKKLLSQQVDSVFKKY 54 
E.ano_Ag1_bla2980                                   -MIKKLGFLFL-----FALLFSCKTEQQKTIDRNVVVDSTITAFQTKLTQQQIDTVFKKY 54 
                                                                                                             .   
 
CAK95242.1|blaADC-19|class                          DVPGMAVGVIQNNKKYE-MYYGLQSVQDKKAVNSSTIFELGSVSKLFTATAGGYAKNKGK 106 
ACN62075.1|blaADC-18|class                          DVPGMAVGVIQNNKKYE-IYYGLQSVQDKKAVNSSTIFELGSVSKLFTATAGGYAKAKGK 106 
CAK95238.1|blaADC-23|class                          DVPGMAVGVIQNNKKYE-IYYGLQSVQDKKAVNSSTIFELGSVSKLFTATAGGYAKAKGK 106 
AIT76084.1|blaACC-4|cephalosporin-hydrolyzing       NIPGMSVAVTVNGKNYI-YNYGLAAKQPQQPVTENTLFEVGSLSKTFAATLASYAQVSGK 109 
AAF86700.1|blaACC-1d|cephalosporin-hydrolyzing      NIPGMSVAVTVNGKNYI-YNYGLAAKQPQQSVTENTLFEVGSLSKTFAATLASYAQVSGK 109 
AAF86694.1|blaACC-1b|cephalosporin-hydrolyzing      NIPGMSVAVTVNGKNYI-YNYGLAAKQPQQPVTENTLFEVGSLSKTFAATLASYAQVSGK 109 
AAF86699.1|blaACC-1a|cephalosporin-hydrolyzing      NIPGMSVAVTVNGKNYI-YNYGLAAKQPQQPVTENTLFEVGSLSKTFAATLASYAQVSGK 109 
BAP68758.1|blaACT-35|cephalosporin-hydrolyzing      SVPGMAVAVIYQGKPHY-YTFGKADIAANKPVTPQTLFELGSISKTFTGVLGGDAIARGE 102 
AFU25650.1|blaACT-12|cephalosporin-hydrolyzing      SIPGMAVAVIYQGQPHY-FTFGKADVAANTPVTAQTLFELGSISKTFTGVLGGDAIARGE 102 
AHM76774.1|blaACT-22|cephalosporin-hydrolyzing      SIPGMAVAVIYQGQPHY-FTFGKADVAANTPVTAQTLFELGSISKTFTGVLGGDAIARGE 102 
E.mir_ATCC33958_bla719                              RIPGMQVAIIKNGKIIKLAAYGTANIPFNIPVTVNTLFPINSMTKCFTGTALVKLIENGQ 64 
E.mir_ATCC33958_bla4255|SBL                         PEVGISVGFINNNEEHY-ISYGNLNAESQVQINKNSLFEIASITKILTSNLIAQAVLDHK 97 
E.men_13253_bla2764                                 HFNGS-IAIFKDSTLLYRKDNGFSNFRNKTKIDSNTIFAIGSVSKQFTAALVLLQQEQGK 113 
E.ano_Ag1_bla2980                                   LFNGS-IAVFKDSTLLYRKENGYSNFKSKTKIDNNTIFAIGSVSKQFTAVLILLQKEQGK 113 
                                                       *  :..  :         *      :  :  .::* : *::* ::.          :  
 
CAK95242.1|blaADC-19|class                          ISFDDTPGKYWKKLKNT---PIDQVNLLQLATYTSGNLAL-QFPDEVQ---------TDQ 153 
ACN62075.1|blaADC-18|class                          ISFDDTPGKYWKELKNT---PIDQVNLLQLATYTSGNLAL-QFPDEVQ---------TDQ 153 
CAK95238.1|blaADC-23|class                          ISFDDTPGKYWKELKNT---PIDQVNLLQLATYTSGNLAL-QFPDEVQ---------TDQ 153 
AIT76084.1|blaACC-4|cephalosporin-hydrolyzing       LSLDQSVSHYVPELRGS---SFDHVSVLNVGTHT-SGLQL-FMPEDIK---------NTT 155 
AAF86700.1|blaACC-1d|cephalosporin-hydrolyzing      LSLDQSVSHYVPELRGS---SFDHVSVLNVGTHT-SGLQL-FMPEDIK---------NTT 155 
AAF86694.1|blaACC-1b|cephalosporin-hydrolyzing      LSLDQSVSHYVPELRGS---SFDHVSVLNVGTHT-SGLQL-FMPEDIK---------NTT 155 
AAF86699.1|blaACC-1a|cephalosporin-hydrolyzing      LSLDQSVSHYVPELRGS---SFDHVSVLNVGTHT-SGLQL-FMPEDIK---------NTT 155 
BAP68758.1|blaACT-35|cephalosporin-hydrolyzing      ISLDDPVTRYWPQLTGK---QWQGIRMLDLATYTAGGLPL-QVPDEVT---------DNA 149 
AFU25650.1|blaACT-12|cephalosporin-hydrolyzing      ISLGDPVTKYWPELTGK---QWQGVRMLDLATYTAGGLPL-QVPDEVT---------DNA 149 
AHM76774.1|blaACT-22|cephalosporin-hydrolyzing      ISLSDPVTKYWPELTGK---QWQGVRMLDLATYTAGGLPL-QVPDEVT---------DNA 149 
E.mir_ATCC33958_bla719                              IKLDDYASVYLSNLP----EPWHKITIKQLLTHTS-GLPDIVDGDTGKM----IVPGEDT 115 
E.mir_ATCC33958_bla4255|SBL                         IKLDDYIDGFLPKEYILHQNLRNKIKISDLASHQS-GLPDIDFAKLIEQDPQQPVNNVTA 156 
E.men_13253_bla2764                                 LKLTDKVSEYLPEFRIKE---YVNISISQLLNHTS-GLNI-------------------- 149 
E.ano_Ag1_bla2980                                   LKLEDKVSQFLPDFRIKE---YENITINQLLNHTS-GLNI-------------------- 149 




CAK95242.1|blaADC-19|class                          QVLTFFKDWKPKNSIGEYRQYSNPSIGLFGKVVALSMNKPFDQVLEKTIFPDLGLKHSY- 212 
ACN62075.1|blaADC-18|class                          QVLTFFKDWKTKNAIGEYRQYSNPSIGLFGKVVALSMNKPFDQVLEKTIFPPLHLKNSY- 212 
CAK95238.1|blaADC-23|class                          QVLTFFKDWKTKNAIGEYRQYSNPSIGLFGKIVALSMNKPFDQVLEKTIFPPLHLKNSY- 212 
AIT76084.1|blaACC-4|cephalosporin-hydrolyzing       QLMAYLKAWKPADAAGTHRVYSNIGTGLLGMIAAKSLGVSYEDAIEKTLLPQLGMHHSY- 214 
AAF86700.1|blaACC-1d|cephalosporin-hydrolyzing      QLMAYLKAWKPADAAGTHRVYSNIGTGLLGMIAAKSLGVSYEDAIEKTLLPQLGMHHSY- 214 
AAF86694.1|blaACC-1b|cephalosporin-hydrolyzing      QLMAYLKAWKPADAAGTHRVYSNIGTGLLGMIAAKSLGMSYEDAIEKTLLPQLGMHHSY- 214 
AAF86699.1|blaACC-1a|cephalosporin-hydrolyzing      QLMAYLKAWKPADAAGTHRVYSNIGTGLLGMIAAKSLGVSYEDAIEKTLLPQLGMHHSY- 214 
BAP68758.1|blaACT-35|cephalosporin-hydrolyzing      SLLRFYQNWQPQWKPGTTRLYANASIGLFGALAVKPSGMPYEQAMTTRVLKPLKLDHTW- 208 
AFU25650.1|blaACT-12|cephalosporin-hydrolyzing      SLLRFYQSWQPQWAPGTTRLYANASIGLFGALAVKPSGMRFEQAMTERVLKPLNLNHTW- 208 
AHM76774.1|blaACT-22|cephalosporin-hydrolyzing      SLLRFYQSWQPQWAPGTTRLYANASIGLFGALAVKPSGMRFEQAMTERVLKPLNLNHTW- 208 
E.mir_ATCC33958_bla719                              IALEKVKTLPIRFAPGEKSEYNQTNYVLLGQIIEKLSKKPFTSFVTEQEFVPANMQQTNF 175 
E.mir_ATCC33958_bla4255|SBL                         QTLATIINNCSELKDYGKYRYSTIGYTLLGQIVEKVYGKTYDEIIRAKIIKPLQMTN-TL 215 
E.men_13253_bla2764                                 ------MGNRLMFKSGTDFYYSNDGFNALGKIVEKVSGKSYDQNITELFTRLGMQHS-ST 202 
E.ano_Ag1_bla2980                                   ------MGNRLMFRSGTGFFYSNDGFNALGQIVEKVSGKSYDENVTELFSKIGLQHS-ST 202 
                                                                        *       :* :        : . :                
 
CAK95242.1|blaADC-19|class                          ---VNVPKTQMQNYAFGYNQENQPIR---------VNPGPLDAPAYGVKSTLPDMLKFIN 260 
ACN62075.1|blaADC-18|class                          ---VNVPKTQMQNYAYGYNQENQPIR---------VNPGPLDAPAYGVKSTLPDMLTFIN 260 
CAK95238.1|blaADC-23|class                          ---VNVPKTQMQNYAYGYNQENQPIR---------VNPGPLDAPAYGVKSTLPDMLTFIN 260 
AIT76084.1|blaACC-4|cephalosporin-hydrolyzing       ---LKVPADQMENYAWGYNKKDEPVH---------GNMEILGNEAYGIKTTSSDLLRYVQ 262 
AAF86700.1|blaACC-1d|cephalosporin-hydrolyzing      ---LKVPADQMENYAWGYNKKDEPVH---------VNMEILGNEAYGIKTTSSDLLRYVQ 262 
AAF86694.1|blaACC-1b|cephalosporin-hydrolyzing      ---LKVPADQMENYAWGYNKKDEPVH---------VNMEILGNEAYGIKTTSSDLLRYVQ 262 
AAF86699.1|blaACC-1a|cephalosporin-hydrolyzing      ---LKVPADQMENYAWGYNKKDEPVH---------VNMEILGNEAYGIKTTSSDLLRYVQ 262 
BAP68758.1|blaACT-35|cephalosporin-hydrolyzing      ---INVPKAEEAHYAWGYRDG-KAVR---------VSPGMLDAQAYGVKTNVQDMANWVM 255 
AFU25650.1|blaACT-12|cephalosporin-hydrolyzing      ---INVPKAEEQHYAWGYRDG-KAVH---------VSPGMLDAEAYGVKTNVKDMASWVV 255 
AHM76774.1|blaACT-22|cephalosporin-hydrolyzing      ---INVPKAEEQHYAWGYRDG-KAVH---------VSPGMLDAEAYGVKTNVKDMASWVV 255 
E.mir_ATCC33958_bla719                              GDSFDVIKNMTESYSYKFNRN-GLWKRSSQLTRVFEEFSILTRPAAGINSTAKELADWLI 234 
E.mir_ATCC33958_bla4255|SBL                         TKDFNVK-NRTT----AHNPDGGIQE--------FFKW-NITAPAGLVKSTASDMVRFLK 261 
E.men_13253_bla2764                                 ALTYKSG-NFAS----AYLGNDKVQELVQNMPERLAEK-EIGTPAGGILSTIDDLHLWNQ 256 
E.ano_Ag1_bla2980                                   ASTFKTG-NFAS----AYLGNDKVQEVVHNMPKRLAGK-EIGTPAGGILSTIDDLHLWNQ 256 
                                                        .            .       .              :   *  : :.  ::  :   
 
CAK95242.1|blaADC-19|class                          ANLNPQKYP--K--DIQRAINETHQGFYQVGTMYQALGWEEFSYPALLQTLLDSNSEQIV 316 
ACN62075.1|blaADC-18|class                          ANLNPQKYP--K--DIQRAISETHQGFYQVGTMYQALGWEEFSYPAPLQTLLDSNSEQIV 316 
CAK95238.1|blaADC-23|class                          ANLNPQKYP--K--DIQRAINETHQGFYQVGTMYQALGWEEFSYPASLQTLLDSNSEQIV 316 
AIT76084.1|blaACC-4|cephalosporin-hydrolyzing       ANMGQLKLDANA--KMQQALTATHTGYFKSGEITQDLMWEQLPYPVSLPNLLTGNDMAM- 319 
AAF86700.1|blaACC-1d|cephalosporin-hydrolyzing      ANMGQLKLDANA--KMQQALTATHTGYFKSGEITQDLMWEQLPYPVSLPNLLTGNDMAM- 319 
AAF86694.1|blaACC-1b|cephalosporin-hydrolyzing      ANMGQLKLDANA--KMQQALTATHTGYFKSGEITQDLMWEQLPYPVSLPNLLTGNDMAM- 319 
AAF86699.1|blaACC-1a|cephalosporin-hydrolyzing      ANMGQLKLDANA--KMQQALTATHTGYFKSGEITQDLMWEQLPYPVSLPNLLTGNDMAM- 319 
BAP68758.1|blaACT-35|cephalosporin-hydrolyzing      ANMAPENVA-DA--SLKQGIALAQSRYWRIGSMYQGLGWEMLNWPVEANTVVEGSDSKVA 312 
AFU25650.1|blaACT-12|cephalosporin-hydrolyzing      ANMAPDGVQ-DA--SLKQGMVLAQSRYWRTGSMYQGLGWEMLNWPVEAKTVVEGSDNKVA 312 
AHM76774.1|blaACT-22|cephalosporin-hydrolyzing      ANMAPDGVQ-DA--SLKQGMALAQSRYWRTGSMYQGLGWEMLNWPVEAKTVVEGSDNKVA 312 
E.mir_ATCC33958_bla719                              HLTEGKFIDQKSLKIMWTPSLHNN-----GTTAPRGLGWSVS------------------ 271 
E.mir_ATCC33958_bla4255|SBL                         AVLNKQ----TT---IGKAAIIMERVVYKDEKREMGLGLNI------------------- 295 
E.men_13253_bla2764                                 KLYSGKVLQPETLKKFTEKSAIRHHAVF----GKMGYACGIM------------------ 294 
E.ano_Ag1_bla2980                                   KLYGGKILKPETLKEFTKKSAERQHAVF----GKMGYAYGIM------------------ 294 
                                                                   :       .                                     
 
CAK95242.1|blaADC-19|class                          MKPNKVTAISKE---PSVKMFHKTGSTNGFGTYVVFIPKENIGLVMLTNKRIPNEERIKA 373 
ACN62075.1|blaADC-18|class                          MKPNKVTAISKE---PSVKMFHKTGSTNGFGSYVVFIPKENIGLVMLTNKRIPNEERIKA 373 
CAK95238.1|blaADC-23|class                          MKPNKVTAISKE---PSVKMFHKTGSTNGFGTYVVFIPKENIGLVMLTNKRIPNEERIKA 373 
AIT76084.1|blaACC-4|cephalosporin-hydrolyzing       -TKSVATPIVPPLPPQENVWINKTGSTNGFGAYIAFVPAKKMGIVMLANKNYSIDQRVTV 378 
AAF86700.1|blaACC-1d|cephalosporin-hydrolyzing      -TKSVATPIVPPLPPQENVWINKTGSTNGFGAYIAFVPAKKMGIVMLANKNYSIDQRVTV 378 
AAF86694.1|blaACC-1b|cephalosporin-hydrolyzing      -TKSVATPIVPPLPPQENVWINKTGSTNGFGAYIAFVPAKKMGIVMLANKNYSIDQRVTV 378 
AAF86699.1|blaACC-1a|cephalosporin-hydrolyzing      -TKSVATPIVPPLPPQENVWINKTGSTNGFGAYIAFVPAKKMGIVMLANKNYSIDQRVTV 378 
BAP68758.1|blaACT-35|cephalosporin-hydrolyzing      LAPLPVVEVNPPAPPVKASWVHKTGSTGGFGSYVAFIPEKQIGIVMLANTSYPNPARVEA 372 
AFU25650.1|blaACT-12|cephalosporin-hydrolyzing      LAPLPVAEVNPPAPPVKASWVHKTGSTGGFGSYVAFIPEKELGIVMLANKSYPNPARVEA 372 
AHM76774.1|blaACT-22|cephalosporin-hydrolyzing      LAPLPVAEVNPPAPPVKASWVHKTGSTGGFGSYVAFIPEKKLGIVMLANKSYPNPARVEA 372 
E.mir_ATCC33958_bla719                              ------------LRKQHPFVYGS----GGMRSAMYYYPEDKIGFIILTNLRGANPEKLIE 315 
E.mir_ATCC33958_bla4255|SBL                         ------------VTDDKNTIYMKSGDSMGQSSIICYNRDKKWGIIILLDQRNSKMRQD-L 342 
E.men_13253_bla2764                                 ------------LNTGKPEAYFHSGYVKGSPSLNIYYPGTKTSVIILSNIADENKGKNAV 342 
E.ano_Ag1_bla2980                                   ------------LNTGKPEAYFHSGYVKGSPSLNIYYPETKTSVIILSNIADENKGKNAV 342 
                                                                                *  :   :    : ..::* :       :    
 
CAK95242.1|blaADC-19|class                          AYAV-LN-----------------AIKK-------------------------------- 383 
ACN62075.1|blaADC-18|class                          AYAV-LN-----------------AIKK-------------------------------- 383 
CAK95238.1|blaADC-23|class                          AYAV-LN-----------------AIKK-------------------------------- 383 
AIT76084.1|blaACC-4|cephalosporin-hydrolyzing       AYKI-LS-----------------SLEGNK------------------------------ 390 
AAF86700.1|blaACC-1d|cephalosporin-hydrolyzing      AYKI-LS-----------------SLEGNK------------------------------ 390 
AAF86694.1|blaACC-1b|cephalosporin-hydrolyzing      AYKI-LS-----------------SLEGNK------------------------------ 390 
AAF86699.1|blaACC-1a|cephalosporin-hydrolyzing      AYKI-LS-----------------SLEGNK------------------------------ 390 
BAP68758.1|blaACT-35|cephalosporin-hydrolyzing      AYYI-LE-----------------ALQ--------------------------------- 381 
AFU25650.1|blaACT-12|cephalosporin-hydrolyzing      AYRI-LS-----------------ALQ--------------------------------- 381 
AHM76774.1|blaACT-22|cephalosporin-hydrolyzing      AYRI-LS-----------------ALQ--------------------------------- 381 
E.mir_ATCC33958_bla719                              QLAGFYIPELHP-YTGTGLPPALGLLHTELLKTKYTKSKEIYKKLQLKDSQFNLSEASLN 374 
E.mir_ATCC33958_bla4255|SBL                         -----LN--------------K---IYDTVLK---------------------------- 352 
E.men_13253_bla2764                                 -----FNPHKEIKSITDNLQNVVTDLQQDLLKPVEKKNE--------------------- 376 
E.ano_Ag1_bla2980                                   -----FNPHKEVKNITDNLQNVIVDLQKDLLKPVEHKNE--------------------- 376 
                                                                             :                                   
 
CAK95242.1|blaADC-19|class                          ------------------------------------------------------------ 383 
ACN62075.1|blaADC-18|class                          ------------------------------------------------------------ 383 
CAK95238.1|blaADC-23|class                          ------------------------------------------------------------ 383 
AIT76084.1|blaACC-4|cephalosporin-hydrolyzing       ------------------------------------------------------------ 390 
AAF86700.1|blaACC-1d|cephalosporin-hydrolyzing      ------------------------------------------------------------ 390 
AAF86694.1|blaACC-1b|cephalosporin-hydrolyzing      ------------------------------------------------------------ 390 
AAF86699.1|blaACC-1a|cephalosporin-hydrolyzing      ------------------------------------------------------------ 390 
BAP68758.1|blaACT-35|cephalosporin-hydrolyzing      ------------------------------------------------------------ 381 
AFU25650.1|blaACT-12|cephalosporin-hydrolyzing      ------------------------------------------------------------ 381 
AHM76774.1|blaACT-22|cephalosporin-hydrolyzing      ------------------------------------------------------------ 381 
E.mir_ATCC33958_bla719                              DWGYTLLHIGYMKQAIEIFSLNTQLYPSSGNTYDSLAEAYESSGNKLMALKNYRRSLEYS 434 
E.mir_ATCC33958_bla4255|SBL                         ------------------------------------------------------------ 352 
E.men_13253_bla2764                                 ------------------------------------------------------------ 376 
E.ano_Ag1_bla2980                                   ------------------------------------------------------------ 376 
                                                                                                                 
 
CAK95242.1|blaADC-19|class                          -------------------- 383 
ACN62075.1|blaADC-18|class                          -------------------- 383 
CAK95238.1|blaADC-23|class                          -------------------- 383 
AIT76084.1|blaACC-4|cephalosporin-hydrolyzing       -------------------- 390 
AAF86700.1|blaACC-1d|cephalosporin-hydrolyzing      -------------------- 390 
AAF86694.1|blaACC-1b|cephalosporin-hydrolyzing      -------------------- 390 
AAF86699.1|blaACC-1a|cephalosporin-hydrolyzing      -------------------- 390 
BAP68758.1|blaACT-35|cephalosporin-hydrolyzing      -------------------- 381 
AFU25650.1|blaACT-12|cephalosporin-hydrolyzing      -------------------- 381 
AHM76774.1|blaACT-22|cephalosporin-hydrolyzing      -------------------- 381 
E.mir_ATCC33958_bla719                              PENTNAKEQIKLLDKQIKHH 454 
E.mir_ATCC33958_bla4255|SBL                         -------------------- 352 
E.men_13253_bla2764                                 -------------------- 376 
E.ano_Ag1_bla2980                                   -------------------- 376 
Class C Group 4 
CLUSTAL O(1.2.1) multiple sequence alignment 
 
 
AFM80040.1|blaADC-63|class                          ----------MRFKKISCLLLSPLFIFSTSIYAGNTPKDQEIKKLVDQNFKPLLEKYDVP 50 
CAK95241.1|blaADC-20|class                          ----------MRFKKISCLLLSPLFIFSTSIYADNTPKDQEIKKLVDQNFKPLLDKYDVP 50 
AAF86694.1|blaACC-1b|cephalosporin-hydrolyzing      MRKKMQNTLKL-LSVITCLAATA------QGALAANIDESKIKDTVDDLIQPLMQKNNIP 53 
AAF86700.1|blaACC-1d|cephalosporin-hydrolyzing      MRKKMQNTLKL-LSVITCLAATA------QGALAANIDESKIKDTVDDLIQPLMQKNNIP 53 
AAF86699.1|blaACC-1a|cephalosporin-hydrolyzing      MRKKMQNTLKL-LSVITCLAATA------QGALAANIDESKIKDTVDDLIQPLMQKNNIP 53 
ACS44783.1|blaMOX-5|CMY-1/MOX                       ----MQQRQSILWGALATLMWAG------LAHAGDKAATDPLRPVVDASIRPLLKEHRIP 50 
ACS44784.1|blaMOX-6|CMY-1/MOX                       ----MQQRQSILWGVLPTLMWAG------LAHAGDRAATDPLRPVVDASIRPLLKEHRIP 50 
KGY70007.1|blaMOX-12|CMY-1/MOX                      ----MQQRQSILWGALATLMWAG------LAHAGDKAATDPLRPVVDASIRPLLKEHRIP 50 
ACS44785.1|blaMOX-7|CMY-1/MOX                       ----MQQRQSILWGALATLMWAG------LVHAGDKAATDPLRPVVDASIRPLLKEHRIP 50 
E.men_ATCC13253_bla800                              --------------MIKKLLSFSVLSTGLVLFAQQNIEM-K-----ADSIMKAYHIP--- 37 
E.men_ATCC13253_bla758|SBL                          ----MK--FKLGLRLLAFIFVA-VLS-GFRLSAQDNIHTDK-----IDRYLENIEKNNLD 47 
E.mir_ATCC33958_bla2658|SBL                         --------------MYKTLFTSVLLS-VSSVLLSQSFNKEK-----LDTYFSTLEKNNKF 40 
E.ano_Ag1_bla3306|SBL                               --------------MYKTLFTSALLS-VSSVLLSQSFNKEK-----LDTYFSTLEKNNKF 40 








AFM80040.1|blaADC-63|class                          GMAVGVIQNNKKYEM-YYGLQSVQ---DKKAVNSSTIFELGSVSKLFTGTAGGYAKNKGK 106 
CAK95241.1|blaADC-20|class                          GMAVGVIQNNKKYEM-YYGLQSVQ---DKKTVNSSTIFELGSVSKLFTATAGGYAKNKGK 106 
AAF86694.1|blaACC-1b|cephalosporin-hydrolyzing      GMSVAVTVNGKNYIY-NYGLAAKQ---PQQPVTENTLFEVGSLSKTFAATLASYAQVSGK 109 
AAF86700.1|blaACC-1d|cephalosporin-hydrolyzing      GMSVAVTVNGKNYIY-NYGLAAKQ---PQQSVTENTLFEVGSLSKTFAATLASYAQVSGK 109 
AAF86699.1|blaACC-1a|cephalosporin-hydrolyzing      GMSVAVTVNGKNYIY-NYGLAAKQ---PQQPVTENTLFEVGSLSKTFAATLASYAQVSGK 109 
ACS44783.1|blaMOX-5|CMY-1/MOX                       GMAVAVLKDGKAHYF-NYGVADRE---RAVGVSEQTLFEIGSVSKTLTATLGAYAVVQGG 106 
ACS44784.1|blaMOX-6|CMY-1/MOX                       GMAVAVLKDGKAHYF-NYGVADRE---RAVGVSEQTLFEIGSVSKTLTATLGAYAVVQGS 106 
KGY70007.1|blaMOX-12|CMY-1/MOX                      GMAVAVLKDGKAHYF-NYGVADRE---RAVGVSEQTLFEIGSVSKTLTATLGAYAVVQGG 106 
ACS44785.1|blaMOX-7|CMY-1/MOX                       GMAVAVLKDGKAHYF-NYGVADRE---RAVGVSEQTLFEIGSVSKTLTATLGAYAVVQGS 106 
E.men_ATCC13253_bla800                              EMAYAVVTPDKIVVQHTTGHHRIEEINDKPNADIHDFFHLGSNTKAITGFIAGYLTEQNK 97 
E.men_ATCC13253_bla758|SBL                          VGSISVYKEGKEVYYRNFGKIPG-----QH-FNKNSVYQVGSITKLFTSVLIFKLIESNK 101 
E.mir_ATCC33958_bla2658|SBL                         SGSVAITQDNKLIYTRSVGYSDIE---NKILNSDKTKYRIGSISKTFTAVLILKSFEEGK 97 
E.ano_Ag1_bla3306|SBL                               SGSVAITQDNKLIYTRSVGYSDIE---NKILNSDKTKYRIGSISKTFTAVLILKSFEEGK 97 
                                                      : .:    *       *                  :.:** :* ::.        .   
 
AFM80040.1|blaADC-63|class                          ISFDDKPGKYWKELKNTP---IDQVNLLQLATYTSGNLA----------LQFPDEVQTDQ 153 
CAK95241.1|blaADC-20|class                          ISFDDTSGKYWKELKNTP---IDQVNLLQLATYTSGNLA----------LQFPDEVQTDQ 153 
AAF86694.1|blaACC-1b|cephalosporin-hydrolyzing      LSLDQSVSHYVPELRGSS---FDHVSVLNVGTH-TSGLQ----------LFMPEDIKNTT 155 
AAF86700.1|blaACC-1d|cephalosporin-hydrolyzing      LSLDQSVSHYVPELRGSS---FDHVSVLNVGTH-TSGLQ----------LFMPEDIKNTT 155 
AAF86699.1|blaACC-1a|cephalosporin-hydrolyzing      LSLDQSVSHYVPELRGSS---FDHVSVLNVGTH-TSGLQ----------LFMPEDIKNTT 155 
ACS44783.1|blaMOX-5|CMY-1/MOX                       FELDDKASLFAPWLKGSA---FDNITMGELATYSAGGLP----------LQFPEEVDSLE 153 
ACS44784.1|blaMOX-6|CMY-1/MOX                       FELDDKASLFAPWLKGSV---FDNITMGELATYSAGGLP----------LQFPEEVDSLE 153 
KGY70007.1|blaMOX-12|CMY-1/MOX                      FELDDKASLFAPWLKGSA---FDNITMGELATYSAGGLP----------LQFPEEVDSLE 153 
ACS44785.1|blaMOX-7|CMY-1/MOX                       FELDDKASLFAPWLKGSV---FDNITMGELATYSAGGLP----------LQFPEEVDSLE 153 
E.men_ATCC13253_bla800                              IKWDQKFFDLFPELKDKSNPKYYNITLAQLLQHQAGIQPFTSGAEYQKLPSFKGSKAEKR 157 
E.men_ATCC13253_bla758|SBL                          LSPDTRLSEFFPTIQYSD-----KITIRNLLEHSSGLNNYVKKSGKTVWLKEPRTDA--- 153 
E.mir_ATCC33958_bla2658|SBL                         LKPDDKLSIFFPQIKNAD-----QITISQLLQHRSGIHNITNDNSYMDYYQEPQSEA--- 149 
E.ano_Ag1_bla3306|SBL                               LKPDDKLSLFFPHIKNAD-----QITISQLLQHRSGIHNITDDNSYMDYYQEPQSEA--- 149 
                                                    :. *         ::        .:.: ::  : :.                         
 
AFM80040.1|blaADC-63|class                          QVLTFFKDWKPKNPIGEYRQYSNPSIGLFGKVVALSMNKPFDQVLEKTIFPALGLKHSYV 213 
CAK95241.1|blaADC-20|class                          QVLTFFKDWKPKNPIGEYRQYSNPSIGLFGKVVALSMNKPFDQVLEKTIFPGLGLKHSYV 213 
AAF86694.1|blaACC-1b|cephalosporin-hydrolyzing      QLMAYLKAWKPADAAGTHRVYSNIGTGLLGMIAAKSLGMSYEDAIEKTLLPQLGMHHSYL 215 
AAF86700.1|blaACC-1d|cephalosporin-hydrolyzing      QLMAYLKAWKPADAAGTHRVYSNIGTGLLGMIAAKSLGVSYEDAIEKTLLPQLGMHHSYL 215 
AAF86699.1|blaACC-1a|cephalosporin-hydrolyzing      QLMAYLKAWKPADAAGTHRVYSNIGTGLLGMIAAKSLGVSYEDAIEKTLLPQLGMHHSYL 215 
ACS44783.1|blaMOX-5|CMY-1/MOX                       KMQAYYRQWTPAYSRGSHRQYANPSIGLFGYLAASSMKQPFDRLMEQTMLPGLGLYHTYL 213 
ACS44784.1|blaMOX-6|CMY-1/MOX                       KMQAYYRQWTPAYSPGSHRQYANPSIGLFGYLAASSMKQPFDRLMEQTILPGLGLYHTYL 213 
KGY70007.1|blaMOX-12|CMY-1/MOX                      KMQAYYRQWTPAYSPGSHRQYANPSIGLFGYLAASSMKQPFDRLMEQTILPGLGLYHTYL 213 
ACS44785.1|blaMOX-7|CMY-1/MOX                       KMQAYYRQWTPAYSPGSHRQYANPSIGLFGYLAASSMKQPFDRLMEQTMLPGLGLYHTYL 213 
E.men_ATCC13253_bla800                              QAFAKYLLTLPPVENNKPYNYSNAGYSIAALMMEKVSRKTWEQLVQDVLKDKLKLQYNL- 216 
E.men_ATCC13253_bla758|SBL                          ELFAELKSQKPLFNPGDSVSYSNSGYYLLGKIIEHKYKDNYGNVLRKLITKPNKLLFTNS 213 
E.mir_ATCC33958_bla2658|SBL                         KLVDIITKAGSDFQPDSKYSYSNSGYILLTYILEKVNKKSYAELLKEKITKPLGLNSTYV 209 
E.ano_Ag1_bla3306|SBL                               KLVDIITKAGSDFQPDSKYSYSNSGYILLTYILEKVNKKPYAELLKEKIMKPLGLNSTYV 209 
                                                    :                   *:* .  :   :        :   :.. :     :  .   
 
AFM80040.1|blaADC-63|class                          NVPKTQMQNYAFGYNQENQPI-----RVNPGPLDAPAYGVKSTLPDMLSFIHANLNPQKY 268 
CAK95241.1|blaADC-20|class                          NVPKTQMQNYAFGYNQENQPI-----RVNPGPLDAPAYGVKSTLPDMLKFINANLNPQKY 268 
AAF86694.1|blaACC-1b|cephalosporin-hydrolyzing      KVPADQMENYAWGYNKKDEPV-----HVNMEILGNEAYGIKTTSSDLLRYVQANMGQLKL 270 
AAF86700.1|blaACC-1d|cephalosporin-hydrolyzing      KVPADQMENYAWGYNKKDEPV-----HVNMEILGNEAYGIKTTSSDLLRYVQANMGQLKL 270 
AAF86699.1|blaACC-1a|cephalosporin-hydrolyzing      KVPADQMENYAWGYNKKDEPV-----HVNMEILGNEAYGIKTTSSDLLRYVQANMGQLKL 270 
ACS44783.1|blaMOX-5|CMY-1/MOX                       NVPEQPMGHYAYGYWKEDKPF-----RVTPAMLAEEPYGIKTSSADLLRFVKANISGV-- 266 
ACS44784.1|blaMOX-6|CMY-1/MOX                       NVPEQAMGHYAYGYSKEDKPI-----RVTPGMLADEAYGIKTSSADLLRFVKANISGV-- 266 
KGY70007.1|blaMOX-12|CMY-1/MOX                      NVPEQAMGHYAYGYSKEDKPI-----RVTPGMLADEAYGIKTSSADLLRFVKANISGV-- 266 
ACS44785.1|blaMOX-7|CMY-1/MOX                       TVPEQAMGHYAYGYSKEDKPI-----RVTPGMLADEAYGIKTSSADLLRFVKANIGGV-- 266 
E.men_ATCC13253_bla800                              GWPNRTNMNQPWGHWKNPQLESVAPTTAYDLSLAEPAGDISMNIVDYSKFIQLNLQGLAG 276 
E.men_ATCC13253_bla758|SBL                          ALQNPQNVSKSYKFSE----QGWVKNPDFYFKNIIGVGDISSNTSDLNKFINLLFEGRIL 269 
E.mir_ATCC33958_bla2658|SBL                         GKKINSQNNEAYSYSP-----GNKKSAETDMSIPIGAGAIVSNPTDIVKFSNALFNGKLL 264 
E.ano_Ag1_bla3306|SBL                               GKKINSQNNEAYSYSS-----GNKKSAETDMSIPIGAGAVVSNPSDIVKFSNALFNGKLL 264 
                                                               : .                         :  .  *   : .  :      
 
AFM80040.1|blaADC-63|class                          --SADIQRAINETHQGRYQINTMYQALGWEEFSYPATLQTLLDSNSEQIVMKPNKVTAIS 326 
CAK95241.1|blaADC-20|class                          --PKDIQRAINETHQGFYQVGTMYQALGWEEFSYPAPLQTLLDSNSEQIVMKPNKVTAIS 326 
AAF86694.1|blaACC-1b|cephalosporin-hydrolyzing      DANAKMQQALTATHTGYFKSGEITQDLMWEQLPYPVSLPNLLTGNDMAMTKSVATPIVPP 330 
AAF86700.1|blaACC-1d|cephalosporin-hydrolyzing      DANAKMQQALTATHTGYFKSGEITQDLMWEQLPYPVSLPNLLTGNDMAMTKSVATPIVPP 330 
AAF86699.1|blaACC-1a|cephalosporin-hydrolyzing      DANAKMQQALTATHTGYFKSGEITQDLMWEQLPYPVSLPNLLTGNDMAMTKSVATPIVPP 330 
ACS44783.1|blaMOX-5|CMY-1/MOX                       -DNAAMQQAIDLTHQGQYAVGEMTQGLGWERYPYPVSEQTLLAGNSPAMIYNANPAAPAP 325 
ACS44784.1|blaMOX-6|CMY-1/MOX                       -DNAAMQQAIDLTHQGQYAVGEMTQGLGWERYAYPVSEQTLLAGNSAAMIYNANPAAPAP 325 
KGY70007.1|blaMOX-12|CMY-1/MOX                      -DNAAMQQAIDLTHQGQYAVGEMTQGLGWERYAYPVSEQTLLAGNSPAMIYNTNPAAPAP 325 
ACS44785.1|blaMOX-7|CMY-1/MOX                       -DNAAMQQAIDLTHQGQYAVGEMTQGLGWERYAYPVSEQTLLAGNSPAMIYNAIPAVPAP 325 
E.men_ATCC13253_bla800                              KNNILKAKT-----YQYLFNSADHYSIGWANAV--------------------------- 304 
E.men_ATCC13253_bla758|SBL                          EEKNLEVM--------KPVIGKETYGRGLMNFN--------------------------- 294 
E.mir_ATCC33958_bla2658|SBL                         NKESLEKM--------ITI--RDGYGYGLFTAQ--------------------------- 287 
E.ano_Ag1_bla3306|SBL                               NKESLEKM--------ITV--RDGYGYGLFTTQ--------------------------- 287 
                                                                                                                 
 
AFM80040.1|blaADC-63|class                          K-EPSVKMYHKTGSTNGFG----TYVVFIPKENIGLVMLTNKRIPNEERIKAAYVVLNAI 381 
CAK95241.1|blaADC-20|class                          K-EPSVKMFHKTGSTNGFG----TYVVFIPKENIGLVMLTNKRIPNEERIKAAYAVLNAI 381 
AAF86694.1|blaACC-1b|cephalosporin-hydrolyzing      LPPQENVWINKTGSTNGFG----AYIAFVPAKKMGIVMLANKNYSIDQRVTVAYKILSSL 386 
AAF86700.1|blaACC-1d|cephalosporin-hydrolyzing      LPPQENVWINKTGSTNGFG----AYIAFVPAKKMGIVMLANKNYSIDQRVTVAYKILSSL 386 
AAF86699.1|blaACC-1a|cephalosporin-hydrolyzing      LPPQENVWINKTGSTNGFG----AYIAFVPAKKMGIVMLANKNYSIDQRVTVAYKILSSL 386 
ACS44783.1|blaMOX-5|CMY-1/MOX                       AAAGHPVLFKKTGSTNGFG----AYVAFVPAKGIGVVMLANRNYPNEGTLKAGHAILTQL 381 
ACS44784.1|blaMOX-6|CMY-1/MOX                       AARGHPVLFNKTGSTNGFG----AYVAFVPAKGIGIVMLANRNSPIEGTLKAGHAILTQL 381 
KGY70007.1|blaMOX-12|CMY-1/MOX                      AAAGHPVLFNKTGSTNGFG----AYVAFVPAKGIGVVMLANRNYPNEARIKAAHAILTKL 381 
ACS44785.1|blaMOX-7|CMY-1/MOX                       AAAGHPVLFNKTGSTNGFG----AYVAFVPAKGIGIVMLANRNSPIEARIKAAHAILTQL 381 
E.men_ATCC13253_bla800                              --VNNKKYSDHL-GTDGTFLAYTQINQSEPKAY--IILVNN-GSPEAQDGLFKFL---KI 355 
E.men_ATCC13253_bla758|SBL                          --FHGINFYGNTGGTYGTN----TILVYEPKSKISISLIIN-GEQYERDLFIKDV-VDII 346 
E.mir_ATCC33958_bla2658|SBL                         --FNDLKGFGHAGGIDDFS----SLFAHYNVGNVSFALDSNVSDGYGNNLIAKAL-LSAV 340 
E.ano_Ag1_bla3306|SBL                               --FNDLKGFGHSGGIDDFS----SLFVYYNVGNVSFALDSNVSEGYGNNLIAKAL-LSAV 340 
                                                              .  .                     . :  *                  : 
 
AFM80040.1|blaADC-63|class                          KK---------------------------------------------------------- 383 
CAK95241.1|blaADC-20|class                          KK---------------------------------------------------------- 383 
AAF86694.1|blaACC-1b|cephalosporin-hydrolyzing      EGNK-------------------------------------------------------- 390 
AAF86700.1|blaACC-1d|cephalosporin-hydrolyzing      EGNK-------------------------------------------------------- 390 
AAF86699.1|blaACC-1a|cephalosporin-hydrolyzing      EGNK-------------------------------------------------------- 390 
ACS44783.1|blaMOX-5|CMY-1/MOX                       AR---------------------------------------------------------- 383 
ACS44784.1|blaMOX-6|CMY-1/MOX                       AR---------------------------------------------------------- 383 
KGY70007.1|blaMOX-12|CMY-1/MOX                      AR---------------------------------------------------------- 383 
ACS44785.1|blaMOX-7|CMY-1/MOX                       AR---------------------------------------------------------- 383 
E.men_ATCC13253_bla800                              LKKQYP------------------------------------------------------ 361 
E.men_ATCC13253_bla758|SBL                          FNNHLSIHKS-------------------------------------------------- 356 
E.mir_ATCC33958_bla2658|SBL                         YNKPYDIPEFKTYQADVNDFAKYIGTYASPSFPLKITITTDNTSLKAQATGQSEFTLTPT 400 
E.ano_Ag1_bla3306|SBL                               YNKPYDIPEFKTYQADVNDFAKYIGTYASPTFPLKIAITTDNTSLKAQATGQSEFTLTPT 400 
                                                                                                                 
 
AFM80040.1|blaADC-63|class                          ------------------------------------- 383 
CAK95241.1|blaADC-20|class                          ------------------------------------- 383 
AAF86694.1|blaACC-1b|cephalosporin-hydrolyzing      ------------------------------------- 390 
AAF86700.1|blaACC-1d|cephalosporin-hydrolyzing      ------------------------------------- 390 
AAF86699.1|blaACC-1a|cephalosporin-hydrolyzing      ------------------------------------- 390 
ACS44783.1|blaMOX-5|CMY-1/MOX                       ------------------------------------- 383 
ACS44784.1|blaMOX-6|CMY-1/MOX                       ------------------------------------- 383 
KGY70007.1|blaMOX-12|CMY-1/MOX                      ------------------------------------- 383 
ACS44785.1|blaMOX-7|CMY-1/MOX                       ------------------------------------- 383 
E.men_ATCC13253_bla800                              ------------------------------------- 361 
E.men_ATCC13253_bla758|SBL                          ------------------------------------- 356 
E.mir_ATCC33958_bla2658|SBL                         DKNKFEFSQAGIKMEFYPDKKQFRLL----------- 426 
E.ano_Ag1_bla3306|SBL                               DKNKFEFSQAGIKMEFYPDKKQFRLLQNGLDILFTKE 437  
Class C Group 5 
CLUSTAL O(1.2.1) multiple sequence alignment 
 
 
ACN62070.1|blaADC-41|class                          MRFKKISCLLLSPLFIFSTSI-YAGN-------------------------------TPK 28 
ALA14812.1|blaADC-77|class                          MRFKKISCLLLSPLFIFSTSI-YAGN-------------------------------TPK 28 
ALA14816.1|blaADC-81|class                          MRFKKISCLLLSPLFIFSTSI-YAGN-------------------------------TPK 28 
AIT76094.1|blaDHA-18|class                          -MKKSLSATLISALLAFSA-----PG-------------------------------FSA 23 
AIT76102.1|blaDHA-19|class                          -MKKSLSATLISALLAFSA-----PG-------------------------------FSA 23 
AIT76108.1|blaDHA-13|class                          -MKKSLSATLISALLAFSA-----PG-------------------------------FSA 23 
CCK86742.1|blaCMY-89|class                          MMKKSLCCALLLTASFPTF-----AA-------------------------------AKT 24 
AFK73452.1|blaCMY-81|class                          MMKKSICCALLLTASFSTF-----AA-------------------------------AKT 24 
AIT76099.1|blaCMY-114|class                         MMKKSLCCALLLTASFSTF-----AA-------------------------------AKT 24 
AKO62865.1|blaCMY-128|class                         MMKKSICCALLLTASFSTF-----AA-------------------------------AKT 24 
AFK73449.1|blaCMY-80|class                          MMKKSLCCALLLTASFSTF-----AA-------------------------------AKT 24 
AFZ85212.1|blaCMY-96|class                          MMKKSLCCALLLTASLSTF-----AA-------------------------------AKT 24 
AEI70575.1|blaACT-9|cephalosporin-hydrolyzing       MKTKSLCCALLLSTSCSVL-----AA-------------------------------PMS 24 
ACJ05689.1|blaACT-5|cephalosporin-hydrolyzing       MMKKSLCCALLLGISCSAL-----AA-------------------------------PVS 24 
AHM76779.1|blaACT-19|cephalosporin-hydrolyzing      MMKKSFCCALLLAISGSAL-----AA-------------------------------PVS 24 
E.ano_Ag1_bla622                                    -MKSI-ILIFLISLNVFSQNRESNIQ----------------------SVKQTKADKTIK 36 
E.men_ATCC13253_bla63                               -MKKH-SALFLLSLTLTFTACKKEGGKAQGNDEKYESKLPNYGNVDLNKVFSPEDSKLAD 58 
E.mir_ATCC33958_bla1527|SBL                         -MKKV-IIL-----------------------------------------FIAVSSI--V 15 
E.ano_Ag1_bla2038|SBL                               -MKKV-IFL-----------------------------------------FIAVSSF--V 15 
E.men_ATCC13253_bla597|SBL                          ------------------------------------------------------------ 0 
E.ano_Ag1_bla267|SBL                                ------------------------------------------------------------ 0 
                                                                                                                 
 
ACN62070.1|blaADC-41|class                          DQEIKKLVDQNFKPLLDKYDVPGMAVGVIQNNKKYETYYGLQS-VQDKKAVSSSTIFELG 87 
ALA14812.1|blaADC-77|class                          DQEIKKLVDQNFKPLLEKYDVPGMAVGVIQNNKKYEMYYGLQS-VQDKKAVNSSTIFELG 87 
ALA14816.1|blaADC-81|class                          DQEIKKLVDQNFKPLLEKYDVPGMAVGVIQNNKKYEMYYGLQS-VQDKKAVNRSTIFELG 87 
AIT76094.1|blaDHA-18|class                          ADNVAAVVDSTIKPLMAQQDIPGMAVAVSVKGKPYYFNYGFAD-VQAKQPVTENTLFELG 82 
AIT76102.1|blaDHA-19|class                          ADNVAAVVDSTIKPLMAQQDIPGMAVAVSVKGKPYYFNYGFAD-VQAKQPVTENTLFELG 82 
AIT76108.1|blaDHA-13|class                          ADNVAAVVDSTIKPLMAQQDIPGMAVAVSVKGKPYYFNYGFAD-VQAKQPVTENTLFELG 82 
CCK86742.1|blaCMY-89|class                          EQQIADIVNRTITPLMQEQAIPGMAVAIIYEGKPYYFTWGKAD-IANKHPVTQQTLFELG 83 
AFK73452.1|blaCMY-81|class                          EQQIADIVNRTITPLMQEQAIPGMAVAIIYEGKPYYFTWGKAD-IVNNHPVTQQTLFELG 83 
AIT76099.1|blaCMY-114|class                         EQQIADIVNRTITPLMQEQAIPGMAVAIIYEGKPYYFTWGKAD-IANNHPVTQQTLFELG 83 
AKO62865.1|blaCMY-128|class                         EQQIADIVNRTITPLMQERAIPGMAVAIIYEGKPYYFTWGKAD-IANNHPVTQQTLFELG 83 
AFK73449.1|blaCMY-80|class                          EPQIADIVNRTITPLMQEQAIPGMAVAVIYQGKSYYFTWGKAD-ITNNHPVTQQTLFELG 83 
AFZ85212.1|blaCMY-96|class                          EPQIADIVNRTITPLMQEQAIPGMAVAVIYQGKPYYFTWGKAD-ITNNHPVTQQTLFELG 83 
AEI70575.1|blaACT-9|cephalosporin-hydrolyzing       EKQLSDVVERTVTPLMKAQAIPGMAVAVIYQGQPHYFTFGKAD-VTANKPVTPQTLFELG 83 
ACJ05689.1|blaACT-5|cephalosporin-hydrolyzing       EKQLAEVVANTVTPLMKAQSIPGMAVAVIYQGKPHYYTFGKAD-IAASKPVTPQTLFELG 83 
AHM76779.1|blaACT-19|cephalosporin-hydrolyzing      EKQLAEVVANTVTPLMKTQAIPGMAVAVIYQGKPHYYTFGEAD-IAAKKPVTPQTLFELG 83 
E.ano_Ag1_bla622                                    EPEYINQINELMTKSYERGLFNGNVLVAKKGKIVYQKSFGFTD-ETRKTPLTKNAIFNFG 95 
E.men_ATCC13253_bla63                               KASVVRTIDNYYQHVWEKGDLSGGVLVAKGDDILYEKYRGFAR-ENNTVPITQDVAMHVA 117 
E.mir_ATCC33958_bla1527|SBL                         YGQKEKKLDSLFTSLYAAKEFNGNVLIAEKGKVIYEKSFGLAN-EKTKQKLDKNTVFELA 74 
E.ano_Ag1_bla2038|SBL                               YGQKEKKLDSLFTSLYAAKEFNGNVLVAEKGKVIYEKSFGLAN-EKTKQKLDKNTVFELA 74 
E.men_ATCC13253_bla597|SBL                          ----MKNTTEILDYYINKTKFNGNIMIADGRKVLYTGSFGETFNPGEKQELNRNSVFELA 56 
E.ano_Ag1_bla267|SBL                                ----MKNVFDILENYIKKIKFNGNIMIAERRKVLYAGSFGNNYHPEEKRELSRSSVFELA 56 











ACN62070.1|blaADC-41|class                          SVSKLFTATAGGYAKNKGKISFDDTPGKYWKELKNTPI-DQVNLLQLATYTSGNLALQFP 146 
ALA14812.1|blaADC-77|class                          SVSKLFTATAGGYAKNKGKISFDDTPGKYWKELKNTPI-DQVNLLQLATYTSGNLALQFP 146 
ALA14816.1|blaADC-81|class                          SVSKLFTATAGGYAKNKGKISFDDTPGKYWKELKNTPI-DQVNLLQLATYTSGNLALQFP 146 
AIT76094.1|blaDHA-18|class                          SVSKTFTGVLGAVSVAKKETALNDPAAKYQPELALPQW-KGITLLDLATYTAGGLPLQVP 141 
AIT76102.1|blaDHA-19|class                          SVSKTFTGVLGAVSVAKKEMALNDPAAKYQPELALPQW-KGITLLDLATYTAGGLPLQVP 141 
AIT76108.1|blaDHA-13|class                          SVSKTFTGVLGAVSVAKKEMALNDPAAKYQPELALPQW-KGITLLDLATYTAGGLPLQVP 141 
CCK86742.1|blaCMY-89|class                          SVSKTFNGVLGGDAIARGEIKLSDPVTKYWPELTGKQW-RGISLLHLATYTAGGLPLQIP 142 
AFK73452.1|blaCMY-81|class                          SVSKTFNGVLGGDAIARGEIKLSDPVTKYWPELTGKQW-RGISLLHLATYTAGGLPLQIP 142 
AIT76099.1|blaCMY-114|class                         SVSKTFNGVLGGDAIARGEIKLSDPVTKYWPELTGKQW-RGISLLHLATYTAGGLPLQIP 142 
AKO62865.1|blaCMY-128|class                         SVSKTFNGVLGGDAIARGEIKLSDPVTKYWPELTGKQW-RGISLLHLATYTAGGLPLQIP 142 
AFK73449.1|blaCMY-80|class                          SVSKTFNGVLGGDAIARGEIKLSDPVTKYWPELTGKQW-QGISLLHLATYTAGGLPLQIP 142 
AFZ85212.1|blaCMY-96|class                          SVSKTFNGVLGGDAIARGEIKLSDPVTKYWPELTGKQW-QGISLLHLATYTAGGLPLQIP 142 
AEI70575.1|blaACT-9|cephalosporin-hydrolyzing       SISKTFTGVLGGDAIARGEISLGDPVTKYWPELTGKQW-QGIRMLDLATYTAGGLPLQVP 142 
ACJ05689.1|blaACT-5|cephalosporin-hydrolyzing       SISKTFTGVLGGDAIARGEISLDDPVTRYWPQLTGKQW-QGIRMLDLATYTAGGLPLQVP 142 
AHM76779.1|blaACT-19|cephalosporin-hydrolyzing      SISKTFTGVLGGDAIARGEISLDDPVTKFWPELTGKQW-QGIRMLDLATYTAGGLPLQVP 142 
E.ano_Ag1_bla622                                    SIVKQFNAVAIMMLVERGHLNLDDPISKYNLDLP--KWSEKVTTRHLINYASGIPRIENK 153 
E.men_ATCC13253_bla63                               SVSKPITAMAVMKLIEAGKLKLNEPLTTLFPGFP---Y-PEITVEMLLKQRSGLPKYEHF 173 
E.mir_ATCC33958_bla1527|SBL                         SVSKQFTAMGIVQLEKDGKLSYNDPLTKYFPELG--FY-KLITIDNLLHHTSGLPDYMEL 131 
E.ano_Ag1_bla2038|SBL                               SVSKQFTAMGIVQLEKEGKLSYNDPLTKYFPELS--FY-KPITIDNLLYHTSGLPDYMSL 131 
E.men_ATCC13253_bla597|SBL                          SVSKPFTAFAMLKVLDVYHLSLHTDIRYFLPGFS---Y-KDITLFHLLNHTSGLPDYMDL 112 
E.ano_Ag1_bla267|SBL                                SVSKPFTAFAMLKVMDVYHLSLHTDVKYFLPDFP---Y-EGISVFQLLNHTSGLPDYMEL 112 
                                                    *: * :..          .             :        :    *    :*        
 
ACN62070.1|blaADC-41|class                          DEV--------QTDQQVLTFFKDWKPK--NPIGEYRQYSNPSIGLFGKVVALSMNKPFDQ 196 
ALA14812.1|blaADC-77|class                          DEV--------QTDQQVLTFFKDWKPK--NPIGEYRQYSNPSIGLFGKVVALSMNKPFDQ 196 
ALA14816.1|blaADC-81|class                          DEV--------QTDQQVLTFFKDWQPK--NPIGEYRQYSNPSIGLFGKVVALSMNKPFDQ 196 
AIT76094.1|blaDHA-18|class                          DAV--------KSRADLLNFYQQWQPS--WKPGDMRLYANSSIGLFGALTANAAGMPYEQ 191 
AIT76102.1|blaDHA-19|class                          DAV--------KSRADLLNFYQQWQPS--WKPGDMRLYANSSIGLFGALTANAAGMPYEQ 191 
AIT76108.1|blaDHA-13|class                          DAV--------KSRADLLNFYQQWQPS--WKPGDMRLYANSSIGLFGALTANAAGMPYEQ 191 
CCK86742.1|blaCMY-89|class                          DDV--------TDKAELLRFYQNWQPQ--WTPGAKRLYANSSIGLFGALVVKPSGMSYEE 192 
AFK73452.1|blaCMY-81|class                          DYV--------TDKAELLRFYQNWQPQ--WTPGAKRLYANSSIGLFGALVVKPSGMSYEE 192 
AIT76099.1|blaCMY-114|class                         DYV--------TDKAELLRFYQNWQPQ--WTPGAKRLYANSSIGLFGALVVKPSGMSYEE 192 
AKO62865.1|blaCMY-128|class                         DDV--------TDKTELLRFYQNWQPQ--WTPGAKRLYANSSIGLFGALVVKPSGMSYEE 192 
AFK73449.1|blaCMY-80|class                          DDV--------TDKAALLRFYQNWQPQ--WAPGAKRLYANSSIGLFGALAVKPSGMSYEE 192 
AFZ85212.1|blaCMY-96|class                          DDV--------TDKAALLRFYQNWQPQ--WAPGAKRLYANSSIGLFGALAVKPSGMSYEE 192 
AEI70575.1|blaACT-9|cephalosporin-hydrolyzing       DEV--------TDNTSLLRFYQHWQPQ--WKPGTTRLYANASIGLFGALAVKPSGMNFEQ 192 
ACJ05689.1|blaACT-5|cephalosporin-hydrolyzing       DEV--------TDNAALLRFYQNWQPQ--WKPGTTRLYANASIGLFGALAVKPSGMPFEQ 192 
AHM76779.1|blaACT-19|cephalosporin-hydrolyzing      EEV--------TDNASLLRFYQHWQPQ--WKPGTTRLYANASIGLFGALAVKPSGMRYEQ 192 
E.ano_Ag1_bla622                                    MIV--------PKNDDEAWKILRKTDTLLFEPGKGYRYDNGNVFLQRRIIEKVTGMTFQD 205 
E.men_ATCC13253_bla63                               LEEAKVPKEKFISNQFILDFIVKNKPELARKPDTGFMYCNTNYALLALVVEKTTQMAFPE 233 
E.mir_ATCC33958_bla1527|SBL                         FDK-NWDKKKFATNKDIVEMLAKYKPELLFAPGDKYEYSNTGYALLGLIIEKVSKQSYGD 190 
E.ano_Ag1_bla2038|SBL                               FDK-NWDKKKFATNKDIVDMLAKYKPELLFVPGDKYEYSNTGYALLGLIIEKVSKQSYGD 190 
E.men_ATCC13253_bla597|SBL                          FEK-HWDKTKIADNQDVLAMLSDYHPKIYFQPGGQWDYSNTGYVLLAVILEKITGFSFPE 171 
E.ano_Ag1_bla267|SBL                                FEE-FWDKTIIADNSDVLGLLIALRPKVYFNPGERWDYCNTGYVILAVILEKITGFSFPE 171 
                                                                                         * *    :   :        : : 
 
ACN62070.1|blaADC-41|class                          VLEKTIFPGLGLKHSYVNVPK---NQMQNYAFGYNQENQPIR-VNPGPLDAPA------- 245 
ALA14812.1|blaADC-77|class                          VLEKTIFPALGLKHSYVNVPK---TQMQNYAFGYNQENQPIR-VNPGPLDAPA------- 245 
ALA14816.1|blaADC-81|class                          VLEKTIFPALGLKHSYVNVPK---TQMQNYAFGYNQENQPIR-VNPGPLDAPAYG---A- 248 
AIT76094.1|blaDHA-18|class                          LLTARILAPLGLSHTFITVPE---SVQSRYAYGYKN-KKPVR-VSPGQLDAES------- 239 
AIT76102.1|blaDHA-19|class                          LLTARILAPLGLSHTFITVPE---SAQSQYAYGYKN-KKPVR-VSPEQLDAES------- 239 
AIT76108.1|blaDHA-13|class                          LLTARILAPLGLSHTFITVPE---SAQSQYAYGYKN-KKPVR-VSPGQLDAES------- 239 
CCK86742.1|blaCMY-89|class                          AMTRRVLQPLKLAHTWITVPQ---SEQKNYAWGYRE-GKPVH-VSPGQLDAEA------- 240 
AFK73452.1|blaCMY-81|class                          AMTRRVLQPLKLAHTWITVPQ---SEQKNYAWGYRE-GKPVH-VSPGQLDAEA------- 240 
AIT76099.1|blaCMY-114|class                         AMTRRVLQPLKLAHTWITVPQ---SEQKNYAWGYRE-GKPVH-VSPGQLDAEA------- 240 
AKO62865.1|blaCMY-128|class                         AMTRRVLQPLKLAHTWITVPQ---SEQKNYAWGYRE-GKPVH-VSPGQLDAEA------- 240 
AFK73449.1|blaCMY-80|class                          AMTRRVLQPLKLAHTWIKVPQ---SEQKDYAWGYRE-GKPVH-VSPGQLDAEA------- 240 
AFZ85212.1|blaCMY-96|class                          AMTRRVLQPLKLAHTWITVPQ---NEQKDYAWGYRE-GKAVH-VSPGQLDAEA------- 240 
AEI70575.1|blaACT-9|cephalosporin-hydrolyzing       AMTKRVFKPLKLDHTWINVPK---EEEAHYAWGYRD-GKAIH-VSPGMLDAEA------- 240 
ACJ05689.1|blaACT-5|cephalosporin-hydrolyzing       AMTTRVLKPLKLDHTWINVPK---AEEAHYAWGYRD-GKAVR-VSPGMLDAQA------- 240 
AHM76779.1|blaACT-19|cephalosporin-hydrolyzing      AMTKRVFKPLRLNHTWINVPK---AEAAHYAWGYRD-GKAVH-ISPGMLDAEA------- 240 
E.ano_Ag1_bla622                                    FVTKNIIKPLKMTNSVFDAKSGYKNRTSCYDMDNVRCPE--------------------M 245 
E.men_ATCC13253_bla63                               AMQEIVFKPLKMKHSFIFQEKDISTAARS----FYN---NG--------RRMFPMDYLDL 278 
E.mir_ATCC33958_bla1527|SBL                         YLSKKIFKPLGMANTRVYRSRYKPESISNYALGYVVDSLGNK-KLLDDLGKEYYTYYLDG 249 
E.ano_Ag1_bla2038|SBL                               YLNKKIFKPLGMANTRVYRSRYKPEKISNYALGYVVDSLGNK-KLLDDLGKEYYTYYLDG 249 
E.men_ATCC13253_bla597|SBL                          VLQKYIFRPLGMENTQVYNRRKHPHHISDYAFGVQKNPENNKFMLPDDIEGEEYVYYLDG 231 
E.ano_Ag1_bla267|SBL                                VLKKYIFRPLDMKNTMVYNRRKKPQLIPDYAFGVSNDPETGKLKLPDKIKGEEYVYYLDG 231 
                                                     :   ::  * : .: .                                            
 
ACN62070.1|blaADC-41|class                          ----YGVKSTLPDMLKFINANLNPQKYP-ADIQRAINETHQGFYQVGIMYQALGWEEFSY 300 
ALA14812.1|blaADC-77|class                          ----YGVKSTLPDMLSFINANLNPQKYP-TDIQRAINETHQGRYQVNTMYQALGWEEFSY 300 
ALA14816.1|blaADC-81|class                          --PAYGVKSTLPDMLSFIHANLNPQKYP-ADIQRAINETHQGFYQVNTMYQALGWEEFSY 305 
AIT76094.1|blaDHA-18|class                          ----YGVKSASKDMLRWAEMNMEPSRAGNADLEMAMYLAQTRYYKTAAINQGLGWEMYDW 295 
AIT76102.1|blaDHA-19|class                          ----YGVKSASKDMLRWAEMNMEPSRAGNADLEMAMYLAQTRYYKTAAINQGLGWEMYDW 295 
AIT76108.1|blaDHA-13|class                          ----YGVKSASKDMLRWAEMNMEPSRAGNADLEMAMYLAQTRYYKTAAINQGLGWEMYDW 295 
CCK86742.1|blaCMY-89|class                          ----YGVKSSVIDMARWVQANMDASHVQEKTLQQGIELAQSRYWRIGDMYQGLGWEMLNW 296 
AFK73452.1|blaCMY-81|class                          ----YGVKSSVIDMARWVQANMDASHVQEKTLQQGIELAQSRYWRIGDMYQGLGWEMLNW 296 
AIT76099.1|blaCMY-114|class                         ----YGVKSSVIDMARWVQANMDASHVQEKTLQQGIELAQSRYWRIGDMYQGLGWEMLNW 296 
AKO62865.1|blaCMY-128|class                         ----YGVKSSVIDMARWVQANMDASLVQEKTLQQGIELAQSRYWRIGDMYQGLGWEMLNW 296 
AFK73449.1|blaCMY-80|class                          ----YGVKSSVIDMARWVQVNMDASRVQEKTLQQGIALAQSRYWRIGDMYQGLGWEMLNW 296 
AFZ85212.1|blaCMY-96|class                          ----YGVKSSVIDMARWVQVNMDASRVQEKTLQQGIALAQSRYWRIGDMYQGLGWEMLNW 296 
AEI70575.1|blaACT-9|cephalosporin-hydrolyzing       ----YGVKTNIQDMASWLKANMNPDALSDSTLKQGIALAQSRYWRVGAMYQGLGWEMLNW 296 
ACJ05689.1|blaACT-5|cephalosporin-hydrolyzing       ----YGMKTNVQDMANWVMANMAPENVADASLKQGISLAQSRYWRIGSMYQGLGWEMLNW 296 
AHM76779.1|blaACT-19|cephalosporin-hydrolyzing      ----YGVKTNVQDMANWVMANMAPENIADASLKQGIALAQSRYWRIGSMYQGLGWEMLNW 296 
E.ano_Ag1_bla622                                    EFISGWLWLDINDMYKWIEAMNYNRLISRKSFETLLNNP-YAKEEGGSLG--------SY 296 
E.men_ATCC13253_bla63                               IYGDKNVYTTPRDLYNFSKALFSENFLKPELKN-LIFQP-YSNEKAGINNYGIGFRMKIF 336 
E.mir_ATCC33958_bla1527|SBL                         IVGDGMVNSTTGDLLKWDRALYGDKLVNQKDKD-LIFSS-IVTKDNKDTRYGYGWGVDTK 307 
E.ano_Ag1_bla2038|SBL                               IVGDGMVNSTTGDLLKWDRALYGDKLVNQKDKD-LIFSS-IVTKDNKDTRYGYGWAIDTK 307 
E.men_ATCC13253_bla597|SBL                          IQGDGTVNSTLDDLLIWNNAILEQYHIHEKHLD-IMFEP-TLLSRDRKFPYGLGWEIDEQ 289 
E.ano_Ag1_bla267|SBL                                IQGDGTVNSTLDDLLIWNNAILEQYLVDEKYLD-LMFEP-TVNNEGQVFPYGLGWELDEK 289 
                                                          :     *:  :               .  :                         
 
ACN62070.1|blaADC-41|class                          PAPLQTLLDSNSEQIVMKPNKVTAISK---EPSVKMFHKTGSTNGFGTYVVFIPKENIGL 357 
ALA14812.1|blaADC-77|class                          PATLQTLLDSNSEQIVMKPNKVTAISK---EPSVKMYHKTGSTTGFGTYVVFIPKENIGL 357 
ALA14816.1|blaADC-81|class                          PATLQTLLDSNSEQIVMKPNKVTAISK---EPSVKMYHKTGSTNGFGTYVVFIPKENIGL 362 
AIT76094.1|blaDHA-18|class                          PQQKDMIINGVTNEVALQPHPVTD-NQVQPYNRASWVHKTGATTGFGAYVAFIPEKQVAI 354 
AIT76102.1|blaDHA-19|class                          PQQKDMIINGVTNEVALQPHPVTD-NQVQPYNRASWVHKTGATTGFGAYVAFIPEKQVAI 354 
AIT76108.1|blaDHA-13|class                          PQQKDMIINGVTNEVALQPHPVTD-NQVQPYNRASWVHKTGATTGFGAYVAFIPEKQVAI 354 
CCK86742.1|blaCMY-89|class                          PLKADSIINGSDSKVALAALPAVEVNPPVPAVKASWVHKTGSTGGFGSYVAFVPEKNLGI 356 
AFK73452.1|blaCMY-81|class                          PLKADSIINGSDSKVALAALPAVEVNPPAPAVKASWVHKTGSTGGFGSYVAFVPEKNLGI 356 
AIT76099.1|blaCMY-114|class                         PLKADSIINGSDSKVALAALPAVEVNPPAPAVKASWVHKTGSTGGFGSYVAFVPEKNLGI 356 
AKO62865.1|blaCMY-128|class                         PLKADSIINGSDSKVALAALPAVEVNPPAPAVKASWVHKTGSTGGFGSYVAFVPEKNLGI 356 
AFK73449.1|blaCMY-80|class                          PLKADSIINGSDSKVALAALPAVEVNPPAPAVKASWVHKTGSTGGFGSYVAFVPEKNLGI 356 
AFZ85212.1|blaCMY-96|class                          PLKADSIINGSDSKVALAALPAVEVNPPAPAVKASWVHKTGSTGGFGSYVAFVPEKNLGI 356 
AEI70575.1|blaACT-9|cephalosporin-hydrolyzing       PVEAKTVVEGSDNKVALAPLLVAEVNPPAPPVKASWVHKTGSTGGFGSYVAFIPEKELGI 356 
ACJ05689.1|blaACT-5|cephalosporin-hydrolyzing       PVEANTVIEGSDSKVALAPLPVAEVNPPAPPVKASWVHKTGSTGGFGSYVAFIPEKQIGI 356 
AHM76779.1|blaACT-19|cephalosporin-hydrolyzing      PVEAKMVIEGSDNKVALAPLPVAEVNPPAPPVKASWVHKTGSTGGFGSYVAFIPEKQIGI 356 
E.ano_Ag1_bla622                                    -FE-----------------------------NEKLQRHNGISHKFESILLNDMKNDIIV 326 
E.men_ATCC13253_bla63                               DNG------------------------------EKLTYHNGWWHGSNAVFGHLLKSKVTI 366 
E.mir_ATCC33958_bla1527|SBL                         -DP-----------------------------VGKIANHSGGWAGYITYIERDLDHDKTI 337 
E.ano_Ag1_bla2038|SBL                               -YP-----------------------------FGKIANHSGGWAGYITFIERDLDYDKTI 337 
E.men_ATCC13253_bla597|SBL                          RNN-----------------------------VGKVVYHTGSWPGYFTCNSVYLEKGISI 320 
E.ano_Ag1_bla267|SBL                                KNG------------------------------EKQVYHTGGWPGYFTYNSLYLNSGISV 319 
                                                                                      .   :.*      :      .    : 
 
ACN62070.1|blaADC-41|class                          VMLTNKRIPNEERIKAAYAVLNAIKK---------------------------------- 383 
ALA14812.1|blaADC-77|class                          VMLTNKRIPNEERIKAAYAVLNAIKK---------------------------------- 383 
ALA14816.1|blaADC-81|class                          VMLTNKRIPNEERIKAAYAVLDAIKK---------------------------------- 388 
AIT76094.1|blaDHA-18|class                          VILANKNYPNTERVKAAQAILSALE----------------------------------- 379 
AIT76102.1|blaDHA-19|class                          VILANKNYPNTERVKAAQAILSALE----------------------------------- 379 
AIT76108.1|blaDHA-13|class                          VILANKNYPNTERVKAAQAILSALE----------------------------------- 379 
CCK86742.1|blaCMY-89|class                          VMLANKSYPNPVRVEAAWRILEKLQ----------------------------------- 381 
AFK73452.1|blaCMY-81|class                          VMLANKSYPNPARVEAAWRILEKLQ----------------------------------- 381 
AIT76099.1|blaCMY-114|class                         VMLANKSYPNPARVEAAWRILEKLQ----------------------------------- 381 
AKO62865.1|blaCMY-128|class                         VMLANKSYPNPARVEAAWRILEKLQ----------------------------------- 381 
AFK73449.1|blaCMY-80|class                          VMLANKSYPNPVRVEAAWRILEKLQ----------------------------------- 381 
AFZ85212.1|blaCMY-96|class                          VMLANKSYPNLVRVEAAWRILEKLQ----------------------------------- 381 
AEI70575.1|blaACT-9|cephalosporin-hydrolyzing       VMLANKSYPNPARVEAAYRILSAL------------------------------------ 380 
ACJ05689.1|blaACT-5|cephalosporin-hydrolyzing       VMLANKSYPNPARVEAAYPILDALQ----------------------------------- 381 
AHM76779.1|blaACT-19|cephalosporin-hydrolyzing      VMLANKSYPNPARVEAAYHILDALQ----------------------------------- 381 
E.ano_Ag1_bla622                                    ILASNNLNKVYSLG-------YIIRDIMLGKAYEIPKKSVYRAIRKESFTDINKAKDTYY 379 
E.men_ATCC13253_bla63                               IAIGNKYSSRVYST---LALSGLFEDFPLEKERLS------KELTRLPVDEKPSDAGE-- 415 
E.mir_ATCC33958_bla1527|SBL                         IMLQNNNSEATSSP---VR---QLRNILYDIRSVK-----------VDIATLQKYAGK-Y 379 
E.ano_Ag1_bla2038|SBL                               IILQNNDSEAASSP---VK---QLRNILYDIKPIK-----------VDLATLQKYAGK-Y 379 
E.men_ATCC13253_bla597|SBL                          ILLSNKPDSEEDTE---EKILQTLEDVVFNKEITI---------------PLHY------ 356 
E.ano_Ag1_bla267|SBL                                ILLCNKPDSED-VE---NEMLQKLEDAAFGKKSPR---------------TLYS------ 354 
                                                    :   *:                 :                                     
 
ACN62070.1|blaADC-41|class                          ------------------------------------------------------------ 383 
ALA14812.1|blaADC-77|class                          ------------------------------------------------------------ 383 
ALA14816.1|blaADC-81|class                          ------------------------------------------------------------ 388 
AIT76094.1|blaDHA-18|class                          ------------------------------------------------------------ 379 
AIT76102.1|blaDHA-19|class                          ------------------------------------------------------------ 379 
AIT76108.1|blaDHA-13|class                          ------------------------------------------------------------ 379 
CCK86742.1|blaCMY-89|class                          ------------------------------------------------------------ 381 
AFK73452.1|blaCMY-81|class                          ------------------------------------------------------------ 381 
AIT76099.1|blaCMY-114|class                         ------------------------------------------------------------ 381 
AKO62865.1|blaCMY-128|class                         ------------------------------------------------------------ 381 
AFK73449.1|blaCMY-80|class                          ------------------------------------------------------------ 381 
AFZ85212.1|blaCMY-96|class                          ------------------------------------------------------------ 381 
AEI70575.1|blaACT-9|cephalosporin-hydrolyzing       ------------------------------------------------------------ 380 
ACJ05689.1|blaACT-5|cephalosporin-hydrolyzing       ------------------------------------------------------------ 381 
AHM76779.1|blaACT-19|cephalosporin-hydrolyzing      ------------------------------------------------------------ 381 
E.ano_Ag1_bla622                                    LLKKTSENEYNFENPSELNTLGYELLRAGRI-KESIEIFKLAISEFPKNANLFDSLGEAY 438 
E.men_ATCC13253_bla63                               ------------------------------------------------------------ 415 
E.mir_ATCC33958_bla1527|SBL                         IKKNSKTFEVFFENNKLYVPLNP----QVRLELEAISTNKFKVRDFSPD---------VF 426 
E.ano_Ag1_bla2038|SBL                               TKKNSKTFEVFFENNKLYVPLNP----QVKLELEAISTNKFKVRDFSPD---------VF 426 
E.men_ATCC13253_bla597|SBL                          ------------------------------------------------------------ 356 
E.ano_Ag1_bla267|SBL                                ------------------------------------------------------------ 354 
                                                                                                                 
 
ACN62070.1|blaADC-41|class                          ------------------------------------- 383 
ALA14812.1|blaADC-77|class                          ------------------------------------- 383 
ALA14816.1|blaADC-81|class                          ------------------------------------- 388 
AIT76094.1|blaDHA-18|class                          ------------------------------------- 379 
AIT76102.1|blaDHA-19|class                          ------------------------------------- 379 
AIT76108.1|blaDHA-13|class                          ------------------------------------- 379 
CCK86742.1|blaCMY-89|class                          ------------------------------------- 381 
AFK73452.1|blaCMY-81|class                          ------------------------------------- 381 
AIT76099.1|blaCMY-114|class                         ------------------------------------- 381 
AKO62865.1|blaCMY-128|class                         ------------------------------------- 381 
AFK73449.1|blaCMY-80|class                          ------------------------------------- 381 
AFZ85212.1|blaCMY-96|class                          ------------------------------------- 381 
AEI70575.1|blaACT-9|cephalosporin-hydrolyzing       ------------------------------------- 380 
ACJ05689.1|blaACT-5|cephalosporin-hydrolyzing       ------------------------------------- 381 
AHM76779.1|blaACT-19|cephalosporin-hydrolyzing      ------------------------------------- 381 
E.ano_Ag1_bla622                                    FTNKQYDLALDSYKKAISLGGSNGNAEKMIDKINNLL 475 
E.men_ATCC13253_bla63                               ------------------------------------- 415 
E.mir_ATCC33958_bla1527|SBL                         YEFKIMDD--GSIKCNMSQPAHNM-NEEGIKKI---- 456 
E.ano_Ag1_bla2038|SBL                               YEFKILDD--GSIKCNMSQPAHNM-NEEGIKKI---- 456 
E.men_ATCC13253_bla597|SBL                          ------------------------------------- 356 






 A branch of functional studies is underway for full confirmation and classification of our proposed b-lactamases, but is not the primary focus of this study, given that results are only preliminary they have not been included within the confines of this paper. 
Molecular classification 
As previously mentioned our approach towards confirmation of the extended variety of Elizabethkingia βlactamases will focus on the molecular classifications of this enzyme family. In order to complete this analysis, an investigation of what makes an A,B,C or D β lactamase was necessary. The first β lactamases classified were the penicillinases from Staphylococcus aureus PC1 [10], Bacillus cereus 569/H [11], Bacillus licheniformis 749/C [12], and Escherichia coli/R6K, R-TEM [13,14,7] . B. cereus identified itself over the rest of the groups of β lactamases by showing a catalytic zinc giving rise to the metallo-b-lactamase class, class B [14]. Shortly after the discovery of class B the seuquencing of the AmpC gene from E.coli K-12 showed significant differences in sequence and motif structure than the classes previously described. AmpC is specific for the breakdown of cephalosporin as opposed to those of the A and B class [15]. Among the classes of the Serine B-lactamases, (A and C) there seemed to be one final outlier that was discovered by Huovinen et al. [16]. OXA-10 was the first class D b-Lactamase and serves as a reference for our study.  
 
Table 1. Provided by Karen Bush et al. served as the guidelines utilized in order to be able to confirm Class A SBLs 
As we classified our largest family of b-lactamases, the Class Cs, there was so much diversity and noise within the sequences, that several subgroups were generated in order to be able to further analyze them based on their phylogenetic grouping. Class C b-lactams as previously mentioned house the cephalosporinases. Class C b-lactams tend to be approximately 360 amino acids in their coding sequences, compared to generally less than 310 amino acids for class A and class D enzymes.  
In order for a b-lactamase to be classified as a Serine B-lactamase it is necessary to locate the catalytic serine in a motif with the SerX-X-Lys sequence [15-21]. In addition we located two other conserved sequences across all three classes of β-lactamases as shown in Table 1: (Ser/Tyr)-X-Asn motif and the Lys-(Thr/Ser)-Gly motif. When classifying the Class A SBLs a glutamic acid at or near position 166 is maintained across samples. We only compared one class D enzyme that loosely related to the NCBI database and searched for the conserved sequence of Ser-X-Val, beginning with serine at position 118 [18].  
Conservation of motifs across bla sequences give us insight on the dependent factors for the proper function of these units [21, 22]. As we look to further classify these novel blas, a simple way to differentiate Class B MBLs is to sequester the metallic ions and look for inhibition. Luckily through this bioinformatics analysis of these sequences we have narrowed down the list of possible B class MBLs and further hones in on the classifications of the A, C and D classes. Now within the class of MBLs there is further subdivisions (eight in total) due to the variance of catalysis around and in conjugation with the zinc ion [23,24]. An interesting note within the structural analysis of the MBL subclass B1 and B3 is the fact that they need two Zn2+ ions to complete hydrolysis of b-lactams. In contrast, the members of subclass B2 more efficiently distribute the force Zn2+ provides by using a singular Zn2+ 25.  
 Table 2. Classifies the subclasses of Class B MBLs 
Table 3. Shows key substrates that will be implemented to measure functionality including penicillins 
(benzylpenicillin, carbenicillin, and cloxacillin), early cephalosporins (cephaloridine or cephalothin) 
in contrast to expanded-spectrum cephalosporins (cefotaxime or ceftazidime), the monobactam 
aztreonam, and carbapenems (usually imipenem)7. 
 
Conclusions & Future Directions 
 As can be observed by the conserved motifs and branchings of our phylogenetic studies, Elizabethkingia has developed itself as a genus to be respected and extensively researched. Not only does it putatively house an extensive variety of antibiotic resistence factors, it is a goldmine for β-lactamases. Reiterating what was stated at the beginning of this paper, it is extremely important to monitor organisms like Elizabethkingia as we are actively observing them react to the extreme evolutionary pressure exerted upon them by humanity and our antibiotic dependence.    
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